Clinical pharmacological studies on the interaction between non-steroidal anti-inflammatory drugs and hydrochlorothiazide by Koopmans, P.P.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113224
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
CLINICAL PHARMACOLOGICAL 
STUDIES ON THE INTERACTION 
BETWEEN NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS AND 
HYDROCHLOROTHIAZIDE 
R R Koopmans 

CLINICAL PHARMACOLOGICAL STUDIES ON THE INTERACTION 
BETWEEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND 
HYDROCHLOROTHIAZIDE 

CLINICAL PHARMACOLOGICAL STUDIES ON THE INTERACTION 
BETWEEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND 
HYDROCHLOROTHIAZIDE 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN 
DOCTOR IN DE GENEESKUNDE AAN DE 
KATHOLIEKE UNIVERSITEIT TE NIJMEGEN 
OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. J.H.G.I. GIESBERS 
VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN 
IN HET OPENBAAR TE VERDEDIGEN 
OP DONDERDAG 9 MEI 1985 
DES NAMIDDAGS TE 2 UUR PRECIES 
DOOR 
PETRUS PAULUS KOOPMANS 
GEBOREN TE TEGELEN 
1985 
DRUK: STICHTING STUDENTENPERS NIJMEGEN 
Promotores: Prof. Dr F.W.J. Gribnau 
Prof. Dr C.A.M, van Ginneken 
Co-referent: Dr. Th . Thien 

The investigations presented in this thesis, were performed in the 
out-patient clinic of the Department of Medicine, Division of General 
Internal Medicine, St. Radboud Hospital Nijmegen, The Netherlands. 
The investigations in this thesis were kindly supported by a grant of 
Merck Sharp and Dohme, Haarlem, The Netherlands. 
Voor Rio. 
CONTENTS 
Chapter 1. 11 
General introduction and problem statement. 
Chapter 2. 19 
Pathofysiogical and clinical aspects of the interaction 
between non-steroidal antiinflammatory drugs (NSAID) and 
diuretics: a review. 
Chapter 3. 35 
The influence of non steroidal antiinflammatory drugs 
(NSAID) on the diuretic treatment of mild to moderate es-
sential hypertension. 
Chapter 4. 45 
The urinary excretion of prostaglandins and tromboxane B2-
in healthy volunteers and patients with essential hyper-
tension: a study in males and females and on the influence 
of seminal fluid contamination. 
Chapter 5. 61 
The effects of sulindac and indomethacin on the anti-
hypertensive and diuretic action of hydrochlorothiazide in 
patients with mild to moderate essential hypertension. 
Chapter 6. 77 
High performance liquid chromatographic determination of 
hydrochlorothiazide in plasma and urine. 
Chapter 7. 87 
The influence of indomethacin and sulindac on the effect 
and on kinetics of hydrochlorothiazide in healthy volun-
teers. 
Chapter θ. 99 
Does sulindac influence the kinetics of hydrochlorothia­
zide? A short term interaction study in hypertensive 
patients. 
Chapter 9. m 
The influences of Ibuprofen, diclofenac and sulindac on 
the blood pressure lowering effect of hydrochlorothiazide. 
Chapter 10. 123 
Summary and conclusions. 
Chapter 11. 129 
Nederlandse samenvatting 
Woorden van dank 139 
Curriculum vitae. 141 

CHAPTER 1 
CLINICAL PHARMACOLOGICAL STUDIES ON THE INTERACTION 
BETWEEN NSAID AW) HYDROCHLOROTHIAZIDE: 
GENERAL INTRODUCTION AND PROBLEM STATEMENT 
Thiazide diuretics in hypertension: 
Thiazide diuretics (table 1) have been used succesfully in the treat-
ment of systemic hypertension for over 20-30 years. Chemically this 
class of drugs is related to sulfonamides, and their common basic 
structure is a sulfamyl group. 
Table 1 THIAZIDES AND RELATED 
Chlorothiazide (Chlotride3) 
Hydrochlorothiazide (Dichlotn 
Bendroflumethiazide (Pluryl®) 
Polythiazide (Renese®) 
Hydroflumethiazide (Rontyl®) 
Cyclopenthiazide (Navidrex®) 
Chlorthalidone (Hygroton®) 
DIURETICS 
de®) (Esidrex®) 
The common mechanism of action of these diuretic agents consist of an 
inhibition of sodium and chloride absorption in the proximal segment of 
the distal tubule of the nephron, resulting in an increase of urinary 
excretion of water and sodium^. 
Secondary to the increase of the sodium load in the distal tubule and 
to the hyperaldosteronism, due to sodium loss, also the excretion of 
potassium and hydrogen rises. Other effects of these drugs are a 
diminishing of the urinary excretion of calcium, uric acid and bicarbo-
nate, whereas some members of the group can deteronate glucose meta-
bolism. 
Uptill now the mechanism, by which thiazides lower blood pressure is 
not completely understood. In the beginning of therapy thiazides de-
crease blood pressure probably by a reduction of plasma volume and of 
cardiac output. Then the secondary rise of plasma renin, aldosterone 
and catecholamines, tries to compensate for the consequences of the al-
tered fluid balance. So, after long term treatment the cardiac output 
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is normalized, but a slight reduction of extracellular volume persist. 
The most important difference however, observed with short term treat-
ment is a reduction of the peripheral resistance, as a result of dila-
tation of resistance vessels. Whether this vasodilation is a conse-
quence of a direct effect of the drug on the vessel wall, an altered 
electrolyte balance in the vessel wall, an altered sensitivity of the 
circulation for catecholamines, or is due to stimulation of the synthe-
sis of vasodilating substances e.g. prostaglandins, has been not yet 
completely resolved^-IO. 
Non steroidal antiinflammatory drugs (NSAID) are at present an usual 
treatment for rheumatic diseases e.g. rheumatoid arthritis or osteo-
arthritis. 
NSAID are well known for their sodium retaining properties^'. 
When administered they induce usually a alight increase of body weight, 
mostly not clinically manifest, but sometimes leading to edema^. 
Furthermore both in healthy volunteers and in edematous states e.g. 
congestive heart failure, nephrotic syndrome and cirrhosis with ascit-
es, NSAID have been demonstrated to blunt the action of diuretic drugs, 
particularly of strong acting agents like the loop diuretics. Moreover 
in these circumstances NSAID have been shown to affect kidney function, 
as reflected by a decrease of glomerular filtration rate, or a rise of 
serumcreatinine 13-17# 
The mechanism by which NSAID blunt the action of diuretics and affect 
kidney function resides probably on the common ability of NSAID to in-
hibit the synthesis of prostaglandins^, as these local hormones are 
involved in the modulation of several renal physiological functions and 
blood pressure^',28# However, other mechanisms could also be responsi-
ble for the interaction between NSAID and diuretica. An introduction 
regarding these questions is extensively given in chapter 2. 
In 1980 Watkins et al.'"' reported that the NSAID, indomethacin, eleva-
ted blood pressure in patients treated with thiazide diuretics (fig. 
1). These investigators administered 100 mg indomethacin per day or 
placebo for three weeks to seven patients. They found that indomethacin 
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induced significantly higher blood pressures than placebo both in 
supine and erect position, being 153/101 ± 7/3 mm Hg and 156/109 ± 6/3 
mm Hg on indomethacin and 140/92 ± 6/4 mm Hg and 140/100 ± 4/2 mm Hg on 
placebo respectively. The same was found, when indomethacin was admi­
nistered to patients treated with propranolol. The observation of 
Watkins et al. confirmed the results of several other groups^','D, who 
found the blood pressure lowering effects of diuretics but also of 
other antihypertensive drugs21,22 to be attenuated by NSAID, particu­
larly by indomethacin 23# 
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Fig. 1 The effect ot placebo (P) or indomethacin (I) on blood pressure 
of 7 diuretic treated hypertension patients: mean values and individual 
mean arterial pressure (MAP) 
(Brit Med J 1980; 281: 702-705) 
More recent investigations have yielded conflicting results. Whereas 
some authors found a clear increase of blood pressure, when indometha­
cin was added to various antihypertensives e.g. diuretics, beta-adreno-
receptor blockers or vasodilators, Steiness et al^*, reported only 
small alterations when indomethacin was added to thiazides. In addi­
tion, also no attenuation of the effect of hydralazine by indomethacin, 
could be established, in another study^S, 
PROBLEM STATEhCNT 
The nain object of the present study was to investigate, whether NSAID 
blunt the blood pressure lowering effect of thiazide diuretics in pa­
tients with essential hypertension. 
Attenuation of the blood pressure lowering effect of thiazides by NSAID 
could have impact on clinical practice, when patients with essential 
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hypertension need NSAID e.g. for concomitant osteoarthritis, reumatoid 
arthritis or other rheumatic disorders. 
As diuretic, we selected HYDROCHtOROTHIAZIDE (DICHLOTRIDE®)since the 
antihypertensive effect of this classic representative of the thiazides 
has been established in numerous short and longterm clinical tnals-
2»3,7,8,10
>
 jhe effect of various NSAID on blood pressure was studied 
namely of INDOMETHACIN (INDOCID®), NAPROXEN (NAPROSYNE®), IBUPROFEN 
(BRUFEN®), DICLOFENAC (VOLTAREN®) and SULINDAC (CLINORIL®). 
The latter drug is possibly an exceptional NSAID. In fact sulindac is a 
prodrug, for after oral administration the drug is metabolized in the 
liver into two metabolites i.e. a sulfon and a sulfide metabolite. The 
sulfide metabolite accounts probably completely for the biological ac­
tivity, whereas the sulfon metabolite is inactive29>30
> 
Sulindac differs possibly from other NSAID in its inhibitory effects on 
renal prostaglandin synthesis. Whereas sulindac decreases the systemic 
synthesis of prostaglandins to the same degree, as other NSAID do, it 
possibly does not influence the synthesis of renal prostaglandins and 
indeed several investigators™ι32,3α have found the effect of sul­
indac on renal prostaglandin synthesis, reflected by the urinary excre­
tion of prostaglandins, to be lower than indomethacin or Ibuprofen, 
both in healthy volunteers-^ »З'1 and in patients with renal disease 
•^ and the Bartter syndrome'"' In addition sulindac is observed to 
have less deleterious effects on kidney function than other NSAID", 
probably also as a result of the, mentioned, minor effects on renal 
prostaglandin synthesis. The mechanism for these particular actions is 
attributed to intrarenal conversion of the sulfide into the sulfon 
metabolite, but is not completely understood. 
What makes it still more difficult is the fact, that concflicting re­
sults have been reported on the action of sulindac and some investiga­
tors have found similar effects of sulindac and other NSAID on the kid­
ney and even on the renal prostaglandin synthesis''»-'^. 
Therefore the second aim of this study was to investigate whether sul­
indac differs from other NSAID in effect on the antihypertensive action 
of hydrochlorothiazide. A different and possibly minor effect of sulin­
dac would have consequences for the choice of an appropriate NSAID in 
hypertensive patients with concomitant rheumatic diseases. 
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The third question was whether a possible difference in interaction 
with hydrochlorothiazide between sulindac and other NSAID (e.g. indo-
methacin) could be explained by distinct effects on renal prostaglandin 
synthesis, as reflected by the urinary excretion of prostaglandins. 
Additionally we investigated the value of the urinary excretion of 
prostaglandins as a measure of intrarenal prostaglandin synthesis. 
Fourthly was investigated, whether pharmacokinetic factors could be 
involved in the interaction between hydrochlorothiazide on one hand and 
sulindac or indomethacin on the other. For this purpose a new HPLC 
method for determination of hydrochlorothiazide in plasma and urine was 
developed. 
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CHAPTER 2 
PATHOFYSIOLOGICAL AND CLINICAL ASPECTS OF THE INTERACTION BETWEEN 
NON-STEROIDAL ANTIINFLAMMATORY DRUGS (NSAID) AND DIURETICS: 
A REVIEW 
INTRODUCTION 
Non-steroidal antiinflammatory drugs (NSAID) now have become an inte-
gral part in the treatment of rheumatic diseases e.g. rheumatoid 
arthritis, but also of non-specific locomotor disorders and osteo-
arthritis. In the recent years numerous NSAID have become available, 
consituting several chemical categories including salicylates, dérivât-
es of propionic acid, indoleacetic acid, phenylacetic acid, pyrazolones 
and oxicams (table 1). Despite structural differences, the NSAID, ex-
cept perhaps sulindac, share their antiinflammatory and analgesic pro-
perties, by their common ability to inhibit cyclooxygenase, a major en-
zym in the biosynthesis of prostaglandins^, , · 
Prostaglandins are derivatives of polyunsaturated fatty acids, mainly 
of arachidonic acid. They are ubiquitous distributed in the body and 
are synthesized locally, exerting their action near the site of synthe-
sis. The biological actions of prostaglandins are extremely diverse and 
include for instance vasodilation, smooth muscle contraction, platelet 
aggregation and disaggregation, and gastrointestinal secretion. In the 
kidney prostaglandins participate in the modulation of several physio-
logical functions as glomerular filtration, sodium and water excretion, 
and the secretion of renin by the macula densa. Furthermore prostaglan-
dins are possibly involved in the regulation of renal perfusion. How-
ever, controversial results have been reported from studies on the role 
of prostaglandins in renal autoregulation, particularly in normal cir-
cumstances *.5f6f7fBp 
At present inhibition of prostaglandins synthesis is supposed to be the 
underlying mechanism for the action of NSAID, not only for their anti-
inflammatory properties, but also for most of their adverse effects. 
As prostaglandins have an important influence on kidney function one 
might expect, that NSAID could have deleterious effects on renal func-
tion. However, it has become clear now, that this is generally not the 
case in normal circumstances. By contrast, the administration of NSAID 
has been shown to affect renal function m several pathological condi-
tions (table 2), in which the kidney has been shown to be prostaglandin 
dependent^. One of these is a state of volume depletion. 
Diuretics are widely used in the treatment of edematous states and of 
hypertension. As diuretics may induce, or aggravate, a certain state of 
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Table 1 list of current available non steroidal anti-
inflammatory drugs (NSAID). 
- SALICYLATES 
- aceticsalicylacid (Aspirine®, Ascal®) 
- diflumsal (Dolocid®) 
- INDOLACETICACID DERIVATIVES 
- indomethacin (Indocid®) 
- sulindac (Clinonl®, Arthndex®) 
- tolmetine (Tolectin®) 
- PROPIONACID DERIVATIVES 
- flurbiprofen (Froben®) 
- Ibuprofen (Brufen®) 
- naproxen (Naprosyne®, Femex®) 
- pirprofen (Rengasil®) 
- PYRAZOLON DERIVATES 
- azapropazon (Prolixan®) 
- fenylbutazon (Butazolidine®) 
- oxyfenbutazon (Tandenl®) 
- FENYLACETICACID DERIVATIVES 
- diclofenac (Voltaren®) 
- OXICAMS 
- Piroxicam (Feldene®) 
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Table 2 Clinical and experimental condit 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
function is shown to be prostagl 
in which NSAID may affect kidney 
Low renal perfusion e.g shock 
Extracellular volume depletion (diuret 
Anesthesia, surgery 
Reduced cardiac output 
Renal disease e.g. nephrotic syndrome, 
ions in which renal 
andin dependent 
function. 
ics, salt loss) 
chronic 
glomerulonephritis, lupus glomerulonephritis 
Hepatic cirrhosis with ascites 
Arteriosclerotic vascular disease e.g. in the elderly 
and 
volume depletion, from a theoretical point of view combination of diu­
retics with NSAID might be harmful for the kidney. In addition it is 
well known that NSAID may induce fluid retention, whereas they also can 
alterate the action of diuretics*»5»6f7f8,9,10,11. 
The present article discusses the pharmacodynamic and pharmacokinetic 
mechanisms for the interaction between diuretics and NSAID, and its 
consequences for kidney function, as suggested in literature. Since the 
combination of diuretics and NSAID is not unusual e.g. in elderly pa­
tients with congestive heart failure and concomitant osteoarthritis, 
this interaction may have an important impact on clinical practice. 
NSAID AND DIURETICS IN HEALTHY VOLUNTEERS 
In 1971 Berley and Kendall12 studied 13 human volunteers and found 
that aspirin in a dose of 20 mg/kg reduced the glomerular filtration 
rate (GFR) in 11 of 13 subjects, with a mean reduction of HSo. These 
observations however have not be confirmed in more recent studies. Berg 
et аІІЗ^
 anc
|
 a
 f
e w
 other investigators1^, were unable to document any 
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change of creatinine clearance after aspirin treatment of normal volun­
teers. And now there is the almost common opinion that NSAID e.g. indo-
methacin do not have a regular effect on GFR in normal circumstances-
7>β
φ
 There may be a transient degree of sodium retention, but usually 
this is not manifest in clinical sense, and the same kind of generali­
zation may hold for renal water excretion. 
By contrast in healthy volunteers, who are sodium restricted or treated 
with diuretics, the situation is quite different. When indomethacin 150 
mg/day for 3 days was given to healthy volunteers, who were sodium res­
tricted, a clear and reversible reduction of GFR (measured by 125j_ 
sodiumiothalomate) was observed. In the sodium replete state however 
indomethacin had no deleterious effects on GFR^'. In addition the same 
pattern of reaction was found for the effective renal plasma flow 
(measured with 131J-hippuran). 
Muther et al^" treated 10 healthy subjects, which were deprived of salt 
with aspirin for two weeks, and saw the creatinine clearance and inulin 
clearance to be reduced with 12 and 15 percent respectively. The same 
results have been reported for other NSAID^'. Furthermore Tanket 
al pretreated 12 normal volunteers with indomethacin 50 mg t.i.d. and 
found, the natriuretic effect of an oral dose of 40 mg furosemide to be 
blunted, just as well as the increase of plasma renin activity and al­
dosterone. Other investigators observed also a significant reduction of 
the furosemide and hydrochlorothiazide induced excretion of sodium, on 
treatment with indomethacin'' 01 Τ » 20. In one study also the potassium 
sparing effect of spinonolactone was abolished by indomethacin^, sug­
gesting that prostaglandins may play a role in this particular action 
of this drug. 
Prostа£Іапсіідз
х
 М5АЮ artá the kidney 
Why should the combination of inhibition of prostaglandin synthesis, 
and salt depletion or, diuretic treatment lead to impaired renal func-
tion7 The current hypothesis for this phenomenon is illustrated in fig-
ure I.5»6»7»0. 
As depicted there, activates volume contraction, caused by sodium de-
pletion or diuretic treatment of certain diseases, the synthesis of 
circulatory pressor mechanisms as catecholamines and the renin angio-
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tensin system. These vasoconstrictive substances stimulate the simulta-
neous synthesis of vasodilatory prostaglandins in the kidney to prevent 
a collapse of renal perfusion. So, by augmenting the synthesis of pros-
taglandins, renal perfusion, glomerular filtration, and tubular water 
and sodium transport is maintained. When this prostaglandin mediated 
counterregulatory mechanism is suppressed by drugs that inhibit cyclo-
oxygenase e.g. NSAID impairment of renal hemodynamics results with a 
decline of GFR, a decrease of sodium and water excretion, and a reduc-
tion of the synthesis of renin and aldosterone. Apart from the influen-
ce of both diuretics and NSAID on renal hemodynamics, the interaction 
between both classes of drugs has also been explained by the contribu-
tion of prostaglandins to the action of diuretics e.g. the the effect 
of furosemide and Spironolacton''0. Contrastly this could not be demon-
strated for thiazides^. 
sodium depletion 
diuretics 
shock 
volumedepletion 
inhibition by 
¡'~ NSAID 
• * ι 
Prostaglandinsynthesis \ 
/Renal blood f low /1 
1
 • / GFR ƒ ·• 1 
/Na*,H20,excretion/ 
Figure 1 Schematic representation of the current hypothesis on the role 
of prostaglandins in maintaining renal function during a state of 
volume depletion or in shock. 
£.cl2.3i'3i.y_0Í.'1£r_m£cÍLail:'-£.m5. IPL· І.^£ .interactісю betwee£ NSAID and diure-
tics 
Recently Simmonds^Z et al casted some doubt on the theory that the in­
teraction between NSAID and diuretics is mediated only by the inhibi­
tion of prostaglandins synthesis. These authors studied the influence 
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Catecholamines / 
Renin \ 
• 
Angiotensin Π / 
Aldosterone / 
of flurbiprofen on the diuretic action of furosemide. Flurbiprofen is 
supposed to be a more potent inhibitor of prostaglandin synthesis than 
indomethacm22,however in this study no reduction was found neither 
of urine volume, nor of sodium and potassium excretion. In addition no 
pharmacokinetic explanation could be given. 
Also other investigators have been tried to explain the diuretic-NSAID 
interaction with pharmacokinetic mechanisms: From in vitro and in vivo 
animal studies it has become clear that all diuretics except triamtere-
ne and spironolactone must reach the tubular lumen to be effective. As 
these diuretics are highly bound to serum proteins, they cannot reach 
the tubular lumen by glomerular filtration for only a small fraction of 
the total drug in serum is free in the circulation and can be sieved 
through the glomerulus. These drugs reach the luminal compartment by 
being actively secreted from the blood into the urine at the organic 
acid transport pathway of the straight segment of the proximal tubule. 
Several organic acids can block this secretion of diuretics into the 
tubular lumen, and a number of authors investigated, whether this holds 
also for NSAID2-' as most NSAID are organic acids. Indeed Data et al2* 
and Smith et al25found that indomethacm alters pharmacokinetics of 
furosemide according to this hypothesis. Their results were confirmed 
by Chennavasin et al2^, however this pharmacokinetic interaction did 
not completely explain the alteration of the diuretic response on furo-
semide in this study. 
Table 3 Prostaglandin independent actions of indomethacm. 
1. Inhibition of cyclic AMP degradation 
2. Decrease of cellular efflux of cyclic AMP 
3. Inhibition of cyclic AMP stimulated protein kinase 
4. Compete with aldosterone for mineralocorticoid receptors 
5. Reduce angiotensin II binding to adrenal cells 
6. Alter smooth muscle contrability by inhibition of calcium 
transport 
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By contrast sofar no pharmacokinetic interaction could be established 
between indomethacin and thiazide diuretics27,2e e.g. hydrochloro-
thiazide''. Conversely sulindac, a NSAID, that is supposed to have less 
effect on renal prostaglandin synthesis2|3,29( reduced the renal 
clearance of hydrochlorothiazide'^. 
Eventually it should be taken into account, that NSAID may have also 
other, prostaglandin independent, pharmacodynamic effects. For in-
stance, for indomethacin several of such effects have been reported in 
literature^ (table 3). 
NSAID AND DIURETICS IN DISEASES WITH EDEMA 
The deleterious effect of NSAID for kidney function have been observed 
particularly in patients with congestive heart failure, nephrotic syn-
drome and in hepatic cirrhosis with ascites. In these disorders hemo-
dynamic changes may occur leading to a diminished circulatory volume 
and to stimulation of the renin angiotensin system. Treatment with 
diuretics is nearly always necessary in these circumstances, and this 
may enhance the hemodynamic changes. So, in accordance with the hypo-
thesis as depicted m figure 1, treatment of such patients with NSAID 
might alter kidney function. 
NSAID^ jind^  diuretic^ in_congestiye heart .failure 
Walsh and Venuto'^ observed a few years ago, that the administration 
of indomethacin to a patient with compensated heart failure and gout, 
resulted in an acute deterioration of renal function and marked sodium 
retention. After indomethacin was withdrawn serumcreatinine returned to 
baseline, and on rechallenge an acute rise of serumcreatinine was ob-
served, concurrently with a decrease of the urinary PGE excretion. In 
addition Laiwah™
 et ai reported three cases of patients with conges-
tive heart failure in which indomethacin antagonized the diuretic ef-
fect of furosemide. These clinical observations confirm studies in ani-
mals, in which a decrement of renal function was observed on treatment 
with indomethacin after experimental reduction of cardiac output'^, 
Recently Dzau et al'4 demonstrated that the gravidity of congestive 
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heart failure is important for the effect of NSAID in this disease. 
They administered indomethacin to two groups of patients with conges-
tive heart failure one with hyponatremia and the other with a normal 
plasma sodium. Then the patients were catheterized. In patients with 
hyponatremia a significantly decrease of cardiac output and in increase 
of serum creatinine was observed, whereas the patients with a normal 
plasma sodium had no significant hemodynamic changes on treatment with 
indomethacin. Simultaneously they found the plasma levels of PGE2 and 
PGI2 to be 3 to 10 times higher in patients with congestive heart fail-
ure as compared to normal subjects, with an inverse correlation between 
plasma prostaglandins and plasma sodium within the groups of patients 
with congestive heart failure. These data suggest that prostaglandins 
play a role in maintaining circulating volume in congestive heart fail-
ure, which was already suggested from earlier studies^ . 
NSMD_aj2d_diure_tics_in the j2e£hrotic jjynd_rome_ 
In the patient with the nephrotic syndrome, plasma volume may be reduc-
ed as a result of low plasma oncotic pressure. Since treatment of such 
patients mostly requires sodium restriction mostly combined with diure-
tics, marked hypovolemia often occurs. Treatment with indomethacin has 
been demonstrated not only to reduce proteinuria, but also to decrease 
creatinine clearance. Under these conditions also indomethacin has been 
reported to block the diuretic action of furosemide in four patients 
whereas this effect was even enhanced under sodium restriction^,36# 
NSAH) and^  diuretics _iH_hepatü:_cirrhosis 
A similar situation of diminished circulating volume, may obtain in 
cirrhosis with ascites. When Boyer et al ^7 administered indomethacin 
to 20 patients with alcoholic liver disease on variable sodium intake, 
they observed a decrease of paraaminohippurate clearance from 526 tot 
430 ml/min and in creatinine clearance from 74 to 60 ml/min. The magni-
tude of the changes was the greatest in patients with ascites. Fur-
thermore prostaglandins play possibly an important role in renal sodium 
handling in such a condition, as is stated by several investiga-
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tors-'B'-'^ . Moreover Zipser et al^ studied the effect of indometha-
cin and Ibuprofen in 12 patients with cirrhosis and ascites during so-
dium restriction (10 mmol/day). In seven patients with a sodium excre-
tion of less than 1 mmol/day NSAID treatment decreased the creatinine 
clearance by 7 percent, whereas in the remaining five, whose sodium 
excretion was between 1 and 10 mmol/24 hr, the creatinine clearance 
fell by 35 percent. As in congestive heart failure, these patients had 
high urinary excretions of prostaglandin E, which declined in parallel 
with the changes in creatinine clearance, induced by NSAID. 
In summary there is strong evidence that in pathological conditions 
with edema, NSAID can block the action of diuretics and may induce a 
deterioration of kidney function. However, the number of reports on 
serious deterioration of glomerular filtration rate is remarkably 
limited, in proportion to the extensive use of both diuretics and 
NSAID. 
Therefore the interaction between both classes of drugs and the dele-
terious effects of NSAID for kidney function in edematous states, may 
be limited only to conditions with a markedly diminished circulating 
volume, whereas this is possibly not a major problem in patients with 
mild to moderate congestive heart failure, nephrotic syndrome, or 
cirrhosis with ascites. 
NSAID AM) DIURETICS IN HYPERTENSION 
Diuretics have been used already for 20-30 years succesfully in the 
treatment of hypertension^~4'. They lower blood pressure probably by 
two mechanisms i.e. by a transient reduction of plasma volume, parti-
cularly in the beginning of the therapy, and at long term treatment by 
a decrease in peripheral vascular resistence. Unlike to diseases with 
edema, in this condition, mainly thiazide diuretics are used, which 
have less strong diuretic effects than furosemide and a more prolonged 
action. 
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Conflicting results have been reported in literature on the interaction 
between diuretics and NSAID in hypertension. Watkins et al^B added 
100 mg indomethacin to thiazide diuretics in patients with hypertension 
and found a statistically significant increase of blood pressure and a 
concomitant decrease of the urinary excretion of prostaglandins. The 
observation confirmed earlier reports on the attenuation of the anti­
hypertensive effects of not only diuretics but also of other antihyper­
tensive drugs, including betablockers, ganglion blocking agents, and 
also of Captopril as has been demonstrated recently49-52t gy contrast 
Steiness et аІ^З observed only a slight attenuation of the hypoten­
sive effect of hydochlorothiazide from addition of indomethacin, where­
as sulindac even enhanced its antihypertensive effect. 
Our groupe has conducted a triple crossover study in ten patients 
with essential hypertension, in which indomethacin 50 mg b.i.d. naprox­
en 250 mg b.i.d., or sulindac 200 mg b.i.d. was added for four weeks 
to hydrochlorothiazide 50 mg o.i.d.. It appeared that the antihyperten­
sive effect of hydrochlorothiazide was slightly attenuated after treat­
ment for two weeks with indomethacin, whereas naproxen and sulindac 
tended to enhance the hypotensive effect. After four weeks of treatment 
the effect of all three NSAIO was blunted. Hence the interaction be­
tween NSAID and hydrochlorothiazide appeared to be at the most a trans­
ient phenomenon and apparently of minor clinical importance. 
Summarizing the reports on the interaction between NSAID and diuretics 
in hypertension it can be concluded, that in some patients NSAID may 
attenuate the antihypertensive effect of diuretics, however there is no 
evidence that in major groups of patients blood pressure treatment is 
impaired, when NSAID are administered concomitantly. Maybe in the 
future, investigations possibly reveal subgroups of hypertensive pa­
tients, in which the antihypertensive effect of diuretics is blunted by 
NSAID treatment. 
CONCLUDING REMARKS 
The interaction between NSAID and diuretics has been demonstrated most 
clearly in conditions of severe circulatory volume depletion. In these 
states NSAID may induce a decrease of GFR, lead to severe fluid reten-
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tion, and blunt the saluretic action of diuretics. 
By contrast sofar in hypertension most reports indicate that an atte­
nuation of the antihypertensive effect of diuretics by NSAID can be ex­
pected in only a minority of patients and this is probably not a major 
problem in most patients with essential hypertension. The mechanism for 
the interaction between NSAID and diuretics is probably based on a 
NSAID induced inhibition of prostaglandin synthesis. However other, 
prostaglandin independent, mechanisms, cannot fully be excluded. 
Furthermore it should be stressed that the interaction between NSAID 
and diuretics in congestive heart failure and other diseases with edema 
has mainly been investigated for indomethacin and furosemide, and one 
should be cautious in extrapolations to other drugs. Therefore it could 
be possible, that the interaction between NSAID and diuretics is re­
stricted to strong acting diuretics, which would be in agreement with 
the hypothesis in figure 1. The fact that in hypertension an inter­
action has not consistently been demonstrated, supports this theory, 
since hypertension is generally treated with distally acting diuretics, 
e.g. thiazides. Eventually, one should taken into account that NSAID 
can induce several kidney diseases e.g. papillary necrosis, intersti­
tial nephritis, nephrotic syndrome. A discussion however of these ad­
verse effects, falls beyond the scope of this article?. 
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CHAPTER 3 
THE INFLUENCE OF NON-STEROIDAL ANTIINFLAfflATORY DRUGS (NSAID) ON 
THE DIURETIC TREATMENT OF MILD TO MODERATE ESSENTIAL 
HYPERTENSION 
British Medical Journal 1984; 289: 1492-1494. 
(With permission of the editor) 
INTRODUCTION 
Although it is known from several investigations that inhibition of the 
synthesis of prostaglandins in the kidney by non steroidal antiinflam-
matory drugs (NSAID) can blunt the natriuretic response on diuretic 
therapy, particularly in states of high angiotensin II levels^,',',» 
-',^ , there is less agreement in literature, whether NSAID can influence 
in a clinically important way, the antihypertensive effect of thiazide 
diuretics. 
Several authors reported on the attenuation of the effect of thiazide 
diuretics and other antihypertensives on blood pressure by indomethacin 
in patients with hypertension7,8,9,10,11· For instance, when indometha-
cin was added to various antihypertensive drugs a 14/6 mmHg increase of 
supine blood pressure was observed8 and even a 13/9 mmHg increase in 
patients treated with only thiazide diuretics7. On the other hand 
Steiness et a l ^ found only a slight (statistically not significant) 
increase of blood pressure during treatment with indomethacin whereas 
they observed an additional decrease of blood pressure during treatment 
with sulindac. 
Since sulindac is supposed to have less effects on renal prostaglandin 
synthesis, than other NSAID'-',' , this drug might have advantages, when 
hypertensive patients on diuretics need NSAID for osteoarthritis or 
other rheumatic diseases. 
The present paper reports the results of the treatment of ten patients 
with essential hypertension with hydrochlorothiazide alone, and hydro-
chlorothiazide in combination with indomethacin, naproxen, or sulindac. 
MftTERIALS AM) METHODS 
Ten patients (8 males, 2 females), age 21-65 years (mean 48.4 + 11.3), 
with essential hypertension, were selected from the outpatient-clinic 
for the study. Included were patients with an untreated supine dia-
stolic blood pressure > 85 mmHg. None of the patients had secondary 
hypertension, signs or symptoms of congestive heart failure, aortic 
valve dysfunction, or history of peptic ulcer. All patients gave an in-
formed consent, and the local ethic committee approved the protocol. 
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The trial was designed as an open triple cross-over study, of 28 
weeks. After a washout period of 4-8 weeks, in which all other anti­
hypertensive medication was discontinued, treatment was started with 
hydrochlorothiazide 50 mg/d, then successively indomethacin 50 mg 
b.i.d., naproxen 250 mg b.i.d., and sulindac 200 mg b.i.d. were added 
for 4 weeks in random seguence, and always with an in-between washout 
period of 4 weeks, in which hydrochlorothiazide alone was continued. 
Every 2 weeks the patients visited the outpatient-clinic for measure­
ment of supine and standing blood pressure, pulse rate and bodyweight. 
Every 4 weeks a venous blood sample was drawn for determination of 
plasma electrolytes, serum creatinine, serum albumine, Plasma jtenin 
Activity (PRA), and plasma aldosterone. Furthermore the patients were 
asked to collect 24 h urine for measurement of the excretion of so­
dium, potassium and creatinine, at the end of each treatment period. 
The blood pressure was measured in the supine patient on the right arm 
at two minutes intervals during 25 minutes, using the artenosonde 
1217. For evaluation means of all readings were calculated with ommit-
tance of the first two, and the last readings. At the end of the auto­
matic measurements two blood pressure readings were determined with a 
legally stamped sphygmomanometer on the left arm both in supine and 
standing positions. Phase V of the Korotkoff sounds was considered as 
the diastolic blood pressure. The mean arterial pressure (MAP) was cal­
culated as the sum of the diastolic blood pressure and one third of the 
pulse pressure. 
Patient compliance was established by 2 weekly pill counts, and came to 
a mean of 99!« for both hydrochlorothiazide (range 86-100л) and NSAID 
(range 89-100%). Plasma aldosterone and PRA were determined by radio-
1 / lb immunoassay , 
Statistical analysis was performed with an analysis of variance for a 3 
period latin sguare design: ρ < 0.05 was considered as statistically 
significant. All data are presented as means ±SD, unless indicated 
otherwise. 
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RESULTS 
Mean supine blood pressure, as measured by sphygmomanometer fell in the 
initial hydrochlorothiazide period (week 1-4) from a baseline value of 
143.0/98.5 ± 12/7 mmHg to 133/93 ± 12/7 mmHg at week 4, whereas the 
values for the artenosonde measurements were 136.2/98.5 ± 11/8 mmHg 
and 127/91.7 ± 13/7 mmHg, respectively. During all of the subsequent 
phases of monotherapy with hydrochlorothiazide, the mean blood pres­
sure, both measured by sphygmomanometer and artenosonde, remained 
within 2 or 3 mmHg, of the values reported in the first period. In ad­
dition there were no statistically significant differences between the 
values, measured at week 2 and at week 4 of each period. 
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Fig. 1 Mean supine blood pressure (mmHg) (±SD), measured by sphygmo-
manometerp and artenosonde Щ, and the percentual alteration of body-
weight (AG'o) compared to baseline value, during treatment with indome-
thacin 50 mg b.i.d. (I) sulindac 200 mg b.i.d. (S) and naproxen 250 mg 
b.i.d. (N) in addition to hydrochlorothiazide at 2 and 4 weeks, and 
their preceeding mean blood pressure during treatment with hydrochloro­
thiazide 50 mg/d (H) alone at week 4. 
* ρ < 0.05, compared to H. 
The mean bodyweight decreased from 73.6 ± 12.0 kg at week 0 to 72.5 ± 
12.0 kg at week 4, and was not statistically different in the phases 
38 
with hydrochlorothiazide alone. Fig. 1 shows the mean supine blood 
pressure, measured by sphygmomanometer and artenosonde, and the mean 
percentual change of bodyweight, as compared to baseline values, during 
treatment with indomethacin, sulindac and naproxen in addition to hy-
drochlorothiazide, with the values at the end of their preceeding phas-
es of monotherapy with hydrochlorothiazide. Compared to hydrochloro-
thiazide alone concomitant treatment with indomethacin tended to in-
crease blood pressure values at week 2 and 4, while treatment with 
either sulindac or naproxen showed slight decreases. At week 2 statis-
tically significant higher values for indomethacin, when compared to 
either sulindac or naproxen were observed for supine blood pressure. 
However, at week 4, no significant differences were observed, when 
there was a tendency for mean blood pressure values for all combination 
treatments to revert to values at the end of the phases with monothera-
py. Furthermore, a statistically significant increase of bodyweight was 
observed during treatment with indomethacin both after two and four 
weeks, whereas naproxen and sulindac induced no statistically signifi-
cant alterations in bodyweight. 
Fig. 2 depicts the individual mean arterial pressures (MAP) measured by 
sphygmomanometer during the different treatment phases. A considerable 
variation in MAP response is observed, however, overall there is an in-
crease of blood pressure in most patients (n=7) during indomethacin 
treatment for two weeks, whereas the opposite i.e. decrease or no res-
ponse is found with both sulindac and naproxen in respectively 6 and 7 
patients. At week 4 the blood pressures tend to revert to their initial 
values although they are variable as well. 
Table 1 gives the plasma potassium, plasma aldosterone,the PRA, serum 
albumine, the endogenous creatinine clearance (ECC), and the 24 h uri-
nary excretion of sodium and potassiun at the start of the study, and 
at the end of the phases with combination treatment, and their precee-
ding phase with hydrochlorothiazide monotherapy. Compared with values 
at the start of the study there is a statistically significant decrease 
of plasma potassium (p < 0.005), an increase of plasma aldosterone (p < 
0.05) and PRA (p < 0.01, Wilcoxontest) after treatment with hydro-
chlorothiazide alone. No significant differences for albumine, ECC, and 
24 h urinary excretion of sodium and potassiun were observed. Moreover, 
no statistically significant alterations were found for none of the pa-
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Table 1 
Uhits 
К»" 
Aldosterone 
FRA 
ECC 
Albuiune 
3.96 ± 0.32 
10.0 ± A.O 
1.98 ± 0.69 
114.4 ± 25 
42.3 1.9 
3.22 ± 0.36»" 3.47 ± 0.31t 3.27 ± 0.31»** 3.32 ± 0.46 3.2B ± 0.36**· 3.3Θ ± 0.29 mrol/l 
19.3 ± 4.3* 17.7 ±11.9 24.7 ±10.8* 17.2 ± 9.7 24.5 ±15.4** 14.1 ± 8.7 ng/100 ml 
5.45 ± 3.7** 3.5 ± 2.0 4.08 ± 1.78** 5.4 ± 4.56 5.9 ± 6J36*** 4.0 ± 2.11 rg/ml/h 
111.6 ±24 107.9 ±32 114.8 ±33 110.2 ± 27 115.7 ±27.4 116.9 ±31 ml/min 
41.5 ± 1 . 4 43 ± 1 . 8 41.7 ± 2.9 42.4 ± 2.7 42.2 ± 2.7 41 ± 2.4 g/1 
uvNa·· 
uv к*· 
186.3 ±61.5 
68.2 ± 17.9 
184 ± 75.4 
85.4 ± 32.1 
165 ± 69.8 
86.4 ± 29.0 
218 ± 82.7 
81.7 ± 18.3 
2Ш ± 102.8 
78.8 ± 24.4 
182.1 ± 62.5 
78 ± 32.6 
160 ± 50.6 nroV24 h 
79.5 ± 32.2 imDl/24 h 
* ρ < 0.05, ** ρ < 0.01, *** ρ < 0.005, caipared to pretreatment values (В) 
t ρ < 0.05, ccnpared to preceeding period mth hydrochlorothiazide monotherapy (H) 
fteai plasna potassiun (K*), ріазла aldosterone, plasia reran activity (PRA), endogenous creatinine сіеагатсе (ECC), serun altuiune, aid the 24 
h urinary excretion of sodiun (UV Ma'") and potassiun (UV K*"), before treatment (B) and durirg treabnmt with indanethacin 50 mg b. i .d. ( I ) , 
SLUmdac 200 mg b. i .d. (S) aid гщхаяеп 250 mg b. i .d. (Ν) in addition to hydrochlorothiazide, aid djring their preceeding period vath hydro­
chlorothiazide 50 mg/d (H) alone. 
rameters during treatment with NSAID, compared with values during 
treatment with hydrochlorothiazide alone, with the exception of an in­
crease of plasma potassium (p < 0.05) during indomethacin. 
DISCUSSION 
In this triple cross-over study we found, that addition of a NSAID 
i.e. indomethacin, naproxen, or sulindac did not influence in a clini­
cally important way the antihypertensive effect of hydrochlorothiazide. 
1AO 
130 
120 
110 
100 
90 H 
80 
Fig. 2 Individual mean arterial blood pressure (MAP) during 2 and 4 
weeks treatment with indomethacin 50 mg b.i.d. (I), naproxen 250 mg 
b.i.d. (N), and sulindac 200 mg b.i.d. (S) in combination with hydro­
chlorothiazide, and their preceeding MAP during treatment with hydro­
chlorothiazide 50 mg/d (H) alone. 
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Our data are in contrast to the results of some other studies , , . 
Several factors could be responsible for this difference, for instance: 
differences in study design, time effects, different dosages and also 
the methods for the blood pressure measurement. 
An increase of blood pressure has been observed already, when indome­
thacin was added for one week to diuretic treatment in hypertensive pa­
tients . However, also longer periods up to 6 weeks7,8 have been used 
to demonstrate an interaction between diuretics and NSAID. Therefore, 
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we choose in our three way cross-over study for four week treatment 
periods with NSAID, for, on one hand this time span had been proven to 
be sufficiently long, and on the other, this could also elicit a tempo-
rary interaction. Moreover, wash out periods, also comprising four 
weeks, were used to prevent "carry over" effects, and in order to pro-
vide for similar blood pressure values at the beginning of each NSAID 
treatment period. 
Our results may suggest indeed, a transient interaction, since the ad-
dition of indomethacin for 2 weeks, induced a slight increase (6/3 
mmHg) of blood pressure, whereas naproxen and sulindac tended to 
enhance the antihypertensive effect of hydrochlorothiazide. However, 
after four weeks of treatment with the three NSAID their effects ap-
peared to be blunted, for blood pressure values reverted to baseline. 
In agreement with other investigators7,1* we also observed considerable 
individual variations in blood pressure response on treatment with 
NSAID. 
In accordance with literature addition of indomethacin increased body-
weight, and attenuated the decrease in plasma potassium by hydrochloro-
thiazide1,^,-',*,'. No other statistical significant alterations were 
observed for various biochemical parameters. 
A disadvantage of this study is possibly the open character, as compar-
ed to some double blind placebo controlled studies7,^. However, in con-
trast to these we used a strictly prospective design, and we measured 
blood pressure in each four weekly period at two occasions with both a 
sphygmomanometer (the "subjective method"), and an artenosonde (the 
objective method), the latter being a blind method. Moreover, it is 
stressed that these artenosonde values are means of eight readings per 
patient on each occasion. 
We cannot exclude that higher dosages of the three NSAID had been re-
vealed an important interaction with hydrochlorothiazide. However, an 
increase of blood pressure has been demonstrated with a similar dosage 
of indomethacin7. Conversely, the dosages of the three NSAID are usual 
for the treatment of osteoarthritis and arthritic disorders. Therefore, 
higher dosages would not have been appropriate for the purpose of this 
study i.e. to investigate whether NSAID influence the treatment of 
hypertension, when these drugs are necessary for concomitant locomotor 
diseases. 
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From a theoretical point of view sulindac might be preferred as the 
NSAID of choice in patients treated with thiazides, as it exhibits pos-
sibly minor effects on renal prostaglandin synthesis^,15,16 compared 
to indomethacin and naproxenl. This study, however, does not establish 
the clinical relevance of this difference, as addition of all three 
NSAID to hydrochlorothiazide resulted only in marginal and transient 
effects on blood pressure. 
SUWiARY 
In an open triple cross-over study in ten patients with mild to mode-
rate essential hypertension, the influence was investigated of addition 
of indomethacin 50 mg, naproxen 250 mg or sulindac 200 mg, each twice 
daily for four weeks, to diuretic treatment with hydrochlorothiazide 50 
mg/d. 
During indomethacin a slight increase of blood pressure was observed 
after treatment for two weeks, whereas both sulindac and naproxen tend-
ed to enhance the antihypertensive effect of hydrochlorothiazide. After 
treatment for four weeks, however, the effects of all three NSAID on 
blood pressure appeared to be blunted. Furthermore, bodyweight increas-
ed statistically significant on treatment with indomethacin, but not 
during naproxen or sulindac. No statistically significant alterations 
were found for various biochemical parameters, including plasma elec-
trolytes, serum creatinine, albumin, Plasma Renin Activity (PRA), plas-
ma aldosterone and the 24 h urinary excretion of sodium and potassium, 
with the exception, however, of an increase of plasma potassium during 
indomethacin. 
From these observations it is concluded that the interaction of indo-
methacin, naproxen and sulindac with diuretic treatment of mild to 
moderate essential hypertension seems to be transient and of minor cli-
nical importance. 
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CHAPTER 4 
THE URINARY EXCRETION OF PROSTAGLANDINS AND TROMBOXANE Вг 
IN HEALTHY VOLUNTEERS AND PATIENTS WITH ESSENTIAL 
HYPERTENSION: 
A STUDY IN MALES AND FEMALES, ATD ON THE INFLUENCE OF SEMINAL 
FLUID CONTAMINATION 
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INTRODUCTION 
Some years ago Lee et al.1 postulated that essential hypertension 
could be due to a deficient production of prostaglandins (PGs) . This 
theory was supported by several investigators^»^»^, who observed de­
creased PGs excretions in the urine of patients with essential hyper­
tension. In contrast other investigators observed decreased PG excre­
tions, only in patients with low renin hypertension and not in patients 
with normal or high renin hypertension, whereas also normal and even 
higher excretions of PGs have been reported in hypertensive patients-
5,6,7,8,9,10,11,12# (jp till now, different assay methods and the con­
tamination of urine specimen with seminal fluid, which is well-known to 
contain high PG concentrations, have led to many contradictory observa­
tions. 
In this paper we present the results of the measurements of several 
PGs, i.e. PGE2, PGF2
a
, 6-l<eto-PGF1a and tromboxane B2 (ТхВг), the 
latter two being the major metabolites of PGI2 and ТхАг, respectively, 
in total 24 h urine specimen from healthy volunteers (HV) and patients 
with essential hypertension (EH), making use of a highly specific ra­
dio- immunoassay (RIA) method, developed in our laboratory1'»1^. 
WTERIALS AND METHODS 
To establish the effect of seminal fluid contamination on the PG con­
tent of 24 h urine specimen, the levels of PGE2, PGF2
a
, 6 keto-
PGFi
a
 and ТхВг were measured in 16 consecutive 24 h urine samples 
from one healthy male volunteer (age 39 years), and in 11 consecutive 
24 h samples from one female healthy volunteer (age 32 years). The two 
volunteers were asked to perform their usual daily activities and to 
note days, upon which they had sexual intercourse. Furthermore, serial 
dilutions of seminal fluid were made with non-contaminated urine to de­
tect the minimum amount of seminal fluid, required to cause a change of 
the urinary PG concentrations. Then, excretions of PGs, TxB2 and of so­
dium, potassiLmi and creatinine were measured in two 24 h urine samples 
from 27 healthy volunteers (13 males, mean age 38 ± 9 (SO) years, range 
26-52, and females mean age 32 ± 9 years, range 16-50) and 41 patients 
with essential hypertension (19 males, mean age 43 ± 13 years, range 
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21-65 and 22 females, mean age 41 ± 14 years, range 26-63). The sub-
jects were requested to abstain from sexual intercourse the day before 
and the day of collection of the urine specimen. 
Mean blood pressure (± 5D) in the hypertensive group was 146/99 mmHg ± 
19/9 in the male and 149/97 mmHg + 27/11 in the female patients. 
All patients were without any antihypertensive medication and nonste-
roidal! anti-inflammatory drug (NSAID) for at least two weeks prior to 
the study, and used an unrestricted diet. 
The diagnosis of essential hypertension had been made on the basis of 
medical history, physical examination and laboratory investigations, 
which included plasma electrolytes, endogenous creatinine clearance, 
and unnanalysis. Hypertension was defined as a supine diastolic 
blood pressure greater than 90 mmHg (and for subjects younger than 30 
years, greater than 85 mmHg), measured on at least three different oc-
casions at the out-patient clinic with a sphygmomanometer after a rest 
period of 5-10 minutes (Korotkof V). 
Following collection, representative 50 ml samples of all the 24 h 
urine specimen were stored at -70PC until assayed. Urine sediments were 
microscopically examined for the presence of spermatozoa. Statistical 
analysis was performed by making use of Student's t-test for unpaired 
data. All data are given as mean ± SD, unless otherwise indicated. 
jt^i(iiMunoassay_af £rOstagland ins 
The excretions of PGE2, PGF2a, 6-keto-PGFia and ТхВг in the urine 
specimen samples were determined by highly specific radioimmunoassays 
(RIA) according to the procedures described previously^»^. i
n 
brief, the assays include the following steps: to 1 ml urine samples an 
amount of 17 Bq PG tracer {5,6,11,12,14,15(n)-3H} PGF2a. SP· a c t · 5· 92 
TBq/mmol, Amersham International pic. (U.K.) was added, since it could 
be demonstrated that the addition of a single tntiated PG was suffi­
cient to monitor the similar procedural losses of the four PGs through­
out the next steps. The samples were acidified with 0.1 ml 1 n-HCl to 
pH 3.5, extracted with 2 χ 10 ml ethyl acetate, and the solvent residue 
was applied to gel filtration on Sephadex G-25. An aqueous, low molecu­
lar mass effluent was collected containing the PGs with recoveries of 
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{ H } PGF2a between 50 and 70%. The selected effluent was applied to 
specific radioimmunoassay for PGF2
a
, PGE2, 6-l<eto-PGFi
a>
 and ТхВг 
and the results obtained were corrected for percentage recovery. 
Cross-reactivity at 50% {Ή} PG displacement for the anti-PGF2a 
antiserum was M% with PGFicc. The anti-PGE2i antiserum showed 10.55» 
cross-reaction with PGEj. The anti-6-keto-PGFia antiserum cross-reacted 
12.8% with PGE·), 1.4% with PGE2 and 7Л% with PGF2
a
. The other PGs 
tested (E,F,A,B) gave values of < 0.1% with the antisera used, 
including the one directed toward ТхВг. The PGE2 assay used 
{5,6,B,11,12,14,15(n)- H) PGE2 (Amersham International pic, Amersham, 
U.K.) with a sp. act. of 5.92 TBq/mmol. The tritium labeled prepara­
tions of the 6-keto-PGFi
a
 and the ТхВг assays were 6-l<eto{5,6,8,9,-
11,12,14,15(n)3H} PGF l a and {5,6,8,9,11,12,14,15(n)-
3H} ТхВг (sp. 
act. 6.04 TBq/mmol), respectively, and were purchased from New England 
Nuclear Boston (Mass., USA). Sensitivities of the four assays, as de­
fined at B/Bo=0.9 following logit-log transformation of the assay data, 
were 1.4 fmol PGE2, 8.5 fmol PGF 2 a, 10.0 fmol 6-keto-PGFla, and 
8.4 fmol TxB2 per assay tube. Method blanks were below these sensiti­
vity limits. Intra- and interassay variabilities were calculated from a 
urine pool stored at -70PC . After ten consecutive assays the PGE2 
determinations showed 6.4 and 15%, the РСЕга assay 5.3 and 11%, the 
6-keto-PGFla assay 7.3% and 9.6% and the ТхВг assay 8.1% and 12.5% 
intra- and interassay variability, respectively. 
RESULTS 
Fig. 1 shows the urinary excretion of PGE2 of a male and a female 
healthy volunteer, who collected their 24 h urine specimen on 16 and 11 
consecutive days, respectively. There exists a slight intraindividual 
day-to-day variation in the excretion of PGE2. However, on days upon 
which the volunteers had sexual intercourse, a sharp rise in the amount 
of PGE2 in urine is observed with considerable variations in the ap­
parent excretions of PGE2 between these days. This higher excretion of 
PGE2 has returned to normal, within 24 h. The excretions of both 
PGF2a and 6-keto-PGFl
a
 followed the same pattern although sexual 
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Table 1 
Comparison of the effect of sexual intercourse on the urinary excretions of PGs and the РСЕг/РСЕгц 
ratio as registered longitudinally in a male and a female healthy volunteer 
SEX INTERCOURSE 
male 
+ 
female 
+ 
* mean ± SO 
24 h SAMPLES 
( n o . ) 
11 
5 
9 
2 
PGEj 
2.3+1.6 
51+17 
0.20+0.06 
54+57 
URINARY EXCRETIONS (nmol/24 h ) * OF 
PGF2a 6KPGF l a TxB2 
13.2+4.0 
45+20 
6.9+1.0 
57.5±60 
18.0±4.6 
41 ±10 
6.9±1.0 
29+1B 
2.3+0.9 
2.6±0.3 
1.9±0.4 
2.0±0.3 
RATIO OF 
PGE2/PGF2a 
0.15±0.12 
1.2±0.3 
0.03±0.008 
0.90±0.05 
CO 
PGE 2 nmol / 24 h 
100 η 
Fig. 1 Excretion of PGE2 in urine on several consecutive days in one 
male (·) and one female (o) healthy volunteer. 
• and Γ I indicate days upon which volunteers had sexual intercourse. 
intercourse showed a slightly less pronounced effect on 6-keto-PGF-|
a 
than on PGF2
a
 (data not shown). Conversely no alterations were ob­
served for TxB2 in either sex. Table 1 depicts the mean urinary ex­
cretions (+ SD) of the PGs, TXB2 as well, as the ratios PGE2/ 
PGF2a f o r the days on which sexual intercourse occurs, as compared to 
days without intercourse. The excretions of PGs are significantly ele­
vated on days with sexual intercourse except for TxB2. Furthermore, 
the ratio PGE2/PGF2
a
 is significantly higher on these days and ap­
proximates a value of 1, while by contrast this ratio is about 0.15 in 
the male and even less (0.03) in the female on the other days. Hence a 
urinary PGE2/PGF2IX ratio of more than 0.5 is considered to be a 
strong indication for contamination of urine specimen with seminal 
fluid. 
From the experiment, in which quantities of seminal fluid were added to 
1 1 non-contaminated urine, it appeared that even an amount of 50 μΐ of 
seminal fluid led to a 14 fold increase of the concentration of PGE2 
(i.e. from 0.26 to 3.7 nmol/24 h) whereas by contrast, the con­
centration of PGF2
a
 just changed from 5.9 to 6.2 nmol/24 h. This re­
sulted in an increase of the PGE2/PGF2
a
 ratio from 0.04 to 0.5Θ. 
The mean excretions (± SD) of the three PGs and ТхВг in total 24 h 
urine (nmol/24 h) (I), the PG-creatinine ratio (nmol/mmol) (II) and the 
PG concentration (nmol/l) (III), in urine are shown in Table 2. The 
urine samples of one female volunteer and of one male hypertensive pa-
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tient were excluded from the study since these samples were probably 
contaminated with seminal fluid on the basis of their elevated PGE2/ 
PGF2(l ratio (2.0 and 1.4, respectively). Thus the healthy volunteer 
group (HV) consisted of 13 males and 13 females, and the group with es­
sential hypertension (EH) consisted of 18 males and 22 females (range 
of PGE2/PGF2
a
 ratio: 0.02-0.3). 
Within the two different groups (i.e. HV and EH) both the mean total 
24 h urine excretions of PGE2 and РС^2а ^ en^ t*16 concentrations 
(III) are always significantly (p < 0.01) higher in males than in fe­
males. The same observations are made for the excretions (I) of 6-
keto-PGF-|
a
 in the EH group and for TxB2 in the HV group. In the 
case of PG/creatinine ratio, significantly higher values can be demon-
TOE2 _ 
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Fig. 2 Individual values (nmol/24 h) (mean of two 24 h urine samples) 
for the excretion of the three PGs and ТхВг; mean + SD in healthy vo­
lunteers (HV) and patients with essential hypertension (EH) are given. 
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Table г 
24 h Urinary excretions of prostaglandins (PG) in nmol/24 h (1), the ratio PG (nmoD/creatinine (mmol) 
IP, and the concentration of the P^s in nmol/l in 24 h urine (HI) of groups of male (M) and female (F) 
lealt^y volunteers 'HV; and for patients with essrntial hypertension (EH) 
I 
M 
F 
II 
M 
F 
ш 
M 
F 
PGC2 
HV 
1.3 
ì 1.0 
'n = 13) 
(b) 
0.50 
i O.Z 
(n = 13) 
CGt2 
HV 
0.09 
i 0.06 
(n = 13) 
(c) 
0.02 
i 0.02 
(n = 13) 
HV 
1.11 
t 0.70 
(n = 13) 
(c) 
0.25 
± 0.20 
(n = 13) 
PGEj 
EH 
1.2 
* 1.2 
(n = IB; 
'b) 
0.31 
• 0.2 
(n = 22) 
EH 
0.07 
í 0.05 
<n = 1Θ) 
(c) 
0.03 
î 0.02 
(n = 22) 
EH 
0.76 
í 0.64 
(n = 18) 
Ce) 
0.23 
t 0.16 
(n = 22) 
HV 
15.0 
* 4.8 
in = 13) 
(b) 
6.1 
i 1.2 
(n = 13) 
Р С Г 2 ( [ 
HV 
O.BB 
i 0.27 
vn = 13) 
(с) 
0.54 
* 0.09 
(η = 13) 
£Η 
11.6 
t 6.4 
Cn = 18) 
(b) 
6.5 
±1.9 
(n = 22) 
CH 
0.67 
t 0.35 
(n = 18) 
0.56 
i 0.21 
(n = 22) 
PGF2Œ 
HV FH 
9.96 
i 3.6В 
(η = 13) 
Cb) 
5.64 
* 3.50 
(η = 13) 
7.89 
t 4.28 
(n = IB) 
(b) 
4.85 
t 2.34 
(n = 22) 
6KPCF 
HV 
7.5 
» 5.3 
(n = 13) 
6.2 
i 1.4 
(π : 13) 
6KPGF 
HV 
0.46 
* 0.23 
ín = 13) 
0.55 
t 0.14 
(n = 13) 
la 
EH 
10.5 
* 6.2 
Cn = 18) 
(b) 
7.2 
± 2.5 
(n = 22) 
la 
EH 
0.62 
i 0.27 
Cn = 18 
0.60 
± 0.18 
(n = 22) 
6KPGF1;I 
HV EH 
5.58 
± 2.ВО 
(n = 13) 
6.40 
± 4.1 
(n = 13) 
7.64 
t 4.49 
(n = 1B) 
(a) 
5.17 
t 2.47 
(n = 22) 
II 
HV 
2.5 
± 1.0 
(n = 13) 
(b) 
1.3 (a) 
± 0.3 
Cn = 13) 
Τι 
HV 
0.14 
i 0.05 
(n = 13) 
0.12 (a 
í 0.02 
(n = 13) 
HV 
1.67 
t 0.39 
(n = 13) 
(a) 
1.29 
i 0.40 
(n = 13) 
<B2 
EH 
2.4 
t 1.0 
(n = 18) 
2.2 
í 1.1 
(n = 22) 
<B2 
EH 
0.15 
* 0.06 
Cn = 18) 
ι) 0.18 
t 0.0Θ 
Cn = 22) 
TxB2 
EH 
1.68 
± 0.93 
(n = 18) 
1.62 
t 1.17 
(n = 22) 
values given as mean i SD 
(a) ρ < 0.05 between HV and EH group, or between sexes 
(b) ρ < 0.01 between sexes 
(c) ρ < O.0O5 between sexes 
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strated for PGE¿ in males of either group and for PGF¿a. in the male HV 
group. 
As shown in Table 3, statistically significant differences are neither 
observed for the mean values of the 24 h urinary excretions of Na+ 
and K+ nor for the urinary volumes between both groups and the 
sexes. The mean excretions of creatinine, however, are significantly 
higher in males, as compared to females in both groups. 
Figure 2 shows the individual mean values of two 24 h urine samples, 
together with the mean excretions (± SD) of the three PGs and TxB2 
for each group. Considerable fluctuations of PGs seem to occur mainly 
in males, particularly for PGF2(I and 6-keto-PGF.ja. 
Comparison of the mean urinary excretions of the PGs and of TxB2 for 
males and for females of either groups shows that statistically signi-
ficant differences can only be demonstrated for the excretion of TxB2 
which was found to be higher in female EH patients. This difference is 
also observed for the TxB2/creatinine ratio but not for the TxB2 
concentration (Table 2). 
Furthermore, no statistically significant correlations could be esta-
blished between excretions of PGs and the excretions of Na+ and K+, 
or the height of the mean arterial blood pressure. 
Comparing the PG excretions in different age groups, it appeared, that 
PGE2 and PGF20 excretions tended to decline gradually with increasing 
age in the male hypertensive group, i.e. PGE2 from 2.46 ± 2.4 ng/24 h 
in subjects younger than 30 years to 0.85 ± 0.Θ ng/24 h in patients ol­
der than 50 years and PGF2a from 17.5 ± 6.6 ng/24 h to 10.4 ± 5.6 ng/24 
h, respectively. By contrast such a trend was not observed for both fe­
male groups, the male healthy volunteers and the excretions of 6-keto-
PGF l a and ТхВг. 
DISCUSSION 
This study presents the measurements of three different PGs and of 
TxB2 in urine of healthy volunteers and patients with essential 
hypertension of either sex. 
Since their discovery, the role of the PGs and thromboxanes in the re­
gulation of blood pressure has been studied extensively. Several PGs, 
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e.g. PGE2 and particular PGI2 have strong vasodilating properties 
and are supposed to be involved in the regulation of blood pressure by 
attenuating the vasoconstrictive actions of angiotensine II, and of 
catecholamines'^»171 whereas by contrast, TxA2 which is also deriv­
ed from polyunsaturated fatty acids has potent vasoconstricting proper-
ііезіб,17,18. 
Several authors have attempted to assess the role of renal PGs in the 
pathogenesis of essential hypertension. Since Frölich et al.19 demon-
strated that urinary PGs mainly reflect their synthesis by the kidney, 
measurement of PGs in urine has become an established method to study 
the alterations of intrarenal PG-synthesis, e.g. in patients with hy-
pertension. 
An important difficulty in the interpretation of results on the excre-
tion of urinary PGs is the possibility that the urine specimens parti-
cularly those from males20>21 are contaminated with seminal fluid, 
which is known to contain extremely high concentrations of PGs. 
In the present study the observations made in two healthy volunteers 
show that urinary excretions of PGE2 rise very strongly on days with 
sexual intercourse for either sex, which is most probably due to conta-
mination of the samples with seminal fluid. The excretions of PGF2a 
are also strongly increased, but less pronounced elevations are observ-
ed for 6-keto-PGFia, whereas the excretions of TXB2 remained un-
changed despite contamination with seminal fluid. Furthermore, this 
contamination leads to a dramatic increase of the PGE2/PGF2a ratio 
to values of approximately 1, while in its absence the same ratio is 
much less than 1. Our experiments, in which serial dilutions were made 
of seminal fluid with non-contaminated urine, clearly demonstrated, 
that this increase of PGs should be attributed to contamination with 
seminal fluid. Addition of even 50 μΐ seminal fluid to non-contaminated 
urine resulted in similar increases of PGE2, P^Za a n^ ^e PGE2/ 
PGF2
a
 ratio, as was found in the two volunteers. 
Our data agree well with those of Benzoni et al.21 and are in accor­
dance with the PG concentrations in seminal fluid, which is known to 
contain much higher PGE2 than РСРга levels22,23# T h e g e results 
also indicate that microscopic inspection of urine samples to detect 
the presence of spermatozoa in urine, is very inappropriate to esta­
blish the presence of seminal fluid. 
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The data reported by several investigators on the measurement of urina-
ry PGs in hypertensive patients are controversial. Partly this may be 
due to different PG assay methods, but also to differences in study de-
sign. The urinary excretions of PGs and TxB2 in patients with essen-
tial hypertension have been found to be lower2»3|4»5,/|8,9
 eqUai6, 
10 or even, to be higher7>11 »^ than normal controls. 
The present study establishes higher 24 h urinary excretions of PGE2 
and PGF2Œ (nmol/24 h) for males than for females. The male group had 
also higher concentrations (nmol/1) of PGE2 and PGF2a in the urine. 
However, the PG/creatinine ratio, which was calculated as a means for 
possibly inadequate urine collecting, indicated, that higher values oc-
curred for the PGE2/creatinine ratio in males, whereas the PGF2a/ 
creatinine ratio was only significantly higher in the group of male 
healthy volunteers. However, one should be careful to draw conclusions 
from the PG/creatinine ratios concerning absolute differences in urina-
ry PG excretions between males and females since it is known, that 
males have in general higher excretions of creatinine than females, as 
was observed also in this study. Several investigators found also 
higher urinary PG excretions^'' in males. 
Up till now, no satisfactory explanation has been reported for the ap-
parent higher PGE2 and PGF2|I excretions in males as compared to fe-
males, since it is as yet not clear, whether males have intrinsic high-
er excretion rates, or whether the differences between sexes might be 
caused by contamination with trace amounts of seminal fluid, which, 
however, apparently did not lead to disturbances of the PGE2/PGF2a 
ratio in our study. 
Furthermore, the present study reports discrepancies for the excretions 
(nmol/24 h) of both 6-keto-PGFia and TxB2 within each group and be-
tween sexes. No reasonable explanation can be given for the latter re-
sults, which are also found for the concentrations (nmol/1) of 6-keto-
PGFia and TxB2 whereas for either PG/creatinine ratios no differen-
ces between males and females at all could be demonstrated. These 
points remain to be further investigated. 
The comparison of the mean PG and TxB2 excretion (nmol/24 h) between 
healthy volunteers and patients with essential hypertension revealed 
no statistically significant differences, with the exception of a high-
er excretion of TxB2 in hypertensive females. However, urinary con-
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centrations (nmol/l) of TxB2 (and also of other PCs) were not higher, 
so the results do not indicate, that TxA2 synthesis is altered in 
hypertensive patients, as is supposed by Hornych et al.11. The pre­
sent data agree in part with those of Lebel et al.^ and of Campbell 
et al.10, however, in the latter study similar excretions, also for 
TxB2, were observed in a group of hypertensive patients and normal 
controls. 
Correlates between the excretions of PGs or TxB2 on the one hand and 
blood pressure, or sodium intake on the other, as reported by others 
24,25,26,27
 a r e n o
t confirmed by the present study. A few investiga­
tors , pointed on the influence of age on the excretion of PGs. We 
found a gradual decline of the excretion of PGE2 (and of РСГг«*) when 
2Θ 
age increases, and this may confirm the results of some groups . How­
ever, we failed to demonstrate such a trend both for the male healthy 
volunteers and for the two female groups, whereas the excretion of 
6-keto-PGF
 α
 and ТхВг did not change with age also. 
The applied radioimmunoassays for the PGs1'»1^ have proved to produce 
valid results, although one could argue that more sophisticated purifi­
cation procedures previous to RIA, e.g. HPLC could possibly provide 
more accurate determinations. Another improvement of assay accuracy and 
specificity might be reached by applying still more specific antisera, 
than the present ones, since it cannot be denied that other cross 
reacting PGs may contribute to the reported results. However, it has 
clearly been shown now, that it is the presence of seminal fluid in the 
urine samples that disturbs the PG measurements, more seriously, than 
what ever could be compensated by more sophisticated analytical proce­
dures. 
In conclusion, it is observed that the basal, 24 h urinary excretions 
of PGs and TxB2 of healthy volunteers are not significantly different 
from those of patients with essential hypertension, with the exception 
of the higher excretion of TxB2 in females with essential hyperten­
sion. Not restricted to males but also in females, the excretion of PGs 
are undoubtedly affected by contamination with trace amounts of seminal 
fluid. Hence the main conclusion from this observation is, that one 
should be extremely careful in drawing conclusions from data on 24 h 
urinary excretions with regard to their renal synthesis. 
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SUtMARY 
Radioimmunoassay measurements of prostaglandins (PGs) £2» F20,6-
keto-PGF-iu and thromboxane (Tx) B2 in 24 h urine specimens from a 
male and a female healthy volunteer on several consecutive days, re­
vealed a dramatic increase of all PGs (except TXB2) and of the 
PGE2/PGF2a ratio to values > 0,5 on days with sexual intercourse. 
This is probably due to contamination of the urine samples by seminal 
fluid. Two 24 h urine samples from each of 26 healthy male and female 
volunteers (HV) and of 40 patients with essential hypertension (EH) re­
vealed in general higher mean PGE2 and F2a values in males than in 
females if expressed as total 24 h excretions, as urinary concentration 
or as excretion/mmol creatinine. 
No consistent differences were observed between groups of EH and HV of 
either sex. 
These results show that the interpretation of urinary PG excretions as 
a measure of renal PG synthesis should be considered carefully. 
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CHAPTER 5 
THE EFFECTS OF SULINDAC AND INDOMETHACIN ON THE ANTIHYPERTENSIVE 
AND DIURETIC ACTION OF HYDROCHLOROTHIAZIDE IN PATIENTS WITH MILD 
TO MODERATE ESSENTIAL HYPERTENSION 
INTRODUCTION 
A few years ago Watkins et al¿' reported a considerable increase of 
blood pressure, when indomethacin was added to both thiazide diuretics 
and betablockers in hypertensive patients. This observation appeared to 
confirm earlier data of a few investigators, who found the blood press-
ure lowering effect of various antihypertensive drugs to be blunted by 
indomethacin^» 21 f28
-
This interaction with antihypertensive agents probably stems from an 
indomethacin induced inhibition of renal prostaglandin synthesis. Pros-
taglandins are derivatives of polyunsaturated fatty acids, particularly 
arachidonic acid. Beside many other actions, they play an important 
role in maintaining several physiological functions of the kidney in-
cluding sodium and water excretion, and the secretion of renin, by 
which they can modulate also the regulation of blood pressure^»14|18# 
Indomethacin shares its prostaglandin synthesis inhibiting properties 
with most, if not all, other non steroidal antiinflammatory drugs 
(NSAID)10. 
Sulindac is possibly an exceptional NSAID. This drug is supposed to 
have minor effects on renal prostaglandin synthesis^»^ »22^ indeed 
Steiness et al23 observed in hypertensive patients no attenuation, 
but even an enhancement of the blood pressure lowering effect of hydro-
chlorothiazide, when sulindac was added. 
By contrast, we were not able to detect a clinical important inter-
action in hypertensive patients between hydrochlorothiazide and three 
different NSAID i.e. indomethacin, naproxen and sulindac^. However 
the number of patients in that study was limited (10) and it was not 
blind. 
Therefore we conducted a trial, in which indomethacin and sulindac were 
added crossover and in double blind random order to hydrochlorothiazide 
in thirty hypertensive patients, using for blood pressure measurements 
both a sphygmomanometer and an artenosonde. In the present article we 
report on the results of this study, which is dealing particularly with 
the possible differences between indomethacin and sulindac in inter-
action with hydrochlorothiazide. Furthermore we have measured the ef-
fects of the two NSAID on the urinary excretion of prostaglandins. 
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MATERIALS AM) tCTHODS 
Thirty patients with mild to moderate essential hypertension were se-
lected from the outpatient clinic. The group consisted of 15 males and 
15 females, mean age 44 ± 11 years (range 21-65). Included were pa-
tients with an untreated supine diastolic blood pressure higher than 85 
mm Hg and lower than 120 mm Hg. Excluded were patients with secondary 
hypertension, signs or symptoms of congestive heart failure, aortic 
valve dysfunction, or a history of peptic ulcer disease. All the pa-
tients gave an informed consent; the ethical committee of the hospi-
tal approved the protocol. 
The study was designed as a crossover study, consisting of seven four-
week periods, preceeded by a variable washout period of four to six 
weeks, in which all antihypertensive medication was discontinued. 
During the whole study the patients took identically looking tablets. 
In the first period (week 1-5) the patients were treated with place-
bos, then with hydrochlorothiazide 50 mg o.i.d. for twenty weeks (week 
5-25), in the third (week 9-13) and the fifth (week 17-21) period, how-
ever were added in double blind random order either indomethacin 50 mg 
b.i.d., or sulindac 200 mg b.i.d.. Finally the study was terminated 
with a second placebo period of four weeks (week 25-29). 
Every two weeks the patients visited the outpatient clinic for measure-
ment of supine blood pressure, pulse rate and bodyweight. At the end of 
each treatment phase a blood sample was drawn for determination of 
electrolytes, creatinine, plasma renin activity (PRA) and aldosterone. 
In addition the patients were requested to collect 24h urine for deter-
mination of sodium, potassium and creatinine. In eleven unselected pa-
tients, the 24h urinary excretion of prostaglandins (PGS) was measured 
each time in two 24h samples. These patients were requested to withold 
from sexual intercourse on both the days of urine collection and on the 
day before. 
The blood pressure was measured in the supine position on the right arm 
at two minutes intervals during 25 minutes using the artenosonde 
1217. For blood pressure evaluation means of all readings were calcu-
lated with omittance of the first, two and the last two readings. At 
the end of the automatic measurements two blood pressure readings were 
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determined with a legally stamped sphygmomanometer on the left arm in 
supine position, Phase V of the Korotkoff sounds was considered as the 
diastolic blood pressure. The mean arterial pressure (MAP) was calcu­
lated as the sum of the diastolic blood pressure and one third of the 
pulse pressure. 
Patient compliance was established by two weekly pill counts and came 
to a mean of 99±2% for hydrochlorothiazide (range 75-100), 9В+2Й for 
sulindac (range Θ2-100) and 97±2S for indomethacin (range 82-100). 
Measurement of PRA, aldosterone and urinary PGE2, PGFjoc, 6 keto PGFia 
and thromboxane B2 (TXB2) were all performed by radioimmunoassay, fol­
lowing methods as described previously^,17,25,26_ 
To assess the degree of interaction of indomethacin or sulindac in pa­
tients, being treated with hydrochlorothiazide, blood pressure, body-
weight and the biochemical parameters, during combination treatment, 
were compared to values at the end of their preceeding period with hy­
drochlorothiazide alone. 
Student t-test for paired data was used to calculate statistical signi­
ficance, Except for PRA, and the excretion of PCs Wilcoxon- test was 
used; ρ < 0.05 was considered to be significant. 
RESULTS 
Six patients did not complete the study. Three patients withdrew,due to 
ineffective therapy at week 8. Two patients were withdrawn due to non­
compliance at week 14, and one patient was discontinued at week 21 by 
his general physician for non trial related reasons. After 4 weeks of 
treatment with hydrochlorothiazide (week 5-9) supine blood pressure of 
this group of 25 patients fell from 143/101 + 15/7 to 132/93 ± 13/8 mm 
Hg, measured by sphygmomanometer, whereas the artenosonde blood press­
ure dropped from 145/101 + 15/7 to 133/94 ± 18/9 mm Hg. 
Blood pressures at week 8, 16, 24 were generally similar within 2-3 mm 
Hg, implying that the response to hydrochlorothiazide alone remained 
stable throughout the study. Only the artenosonde systolic blood 
pressure showed a tendency to fall from 135 ± 8 mm Hg at week 8 to 129 
± 11 at week 24. 
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Figure 1 Supine blood pressure (sphygmomanometer and arterioaonde) and 
bodyweight (BW) in 25 hypertensive patients during treatment 
with placebos (PL), hydrochlorothiazide 50 mg o.i.d. alone (H) 
and hydrochlorothiazide 50 mg o.i.d. in combination with indo-
methacin (I) 50 mg b.i.d. or sulindac (S) 200 mg b.i.d. t ρ < 
0.01, as compared to PL. * ρ < 0.01 as compared to H. 
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Figure 2 Supine blood pressure (mm Hg) (sphygmomanometer and arterio-
sonde) during treatment with placebos (PL), hydrochlorothia­
zide 50 mg o.i.d. alone (H) and hydrochlorothiazide 50 mg 
o.i.d. in combination with indomethacin 50 mg b.i.d. (I) or 
sulindac 200 mg b.i.d. (S), in the two different sequence 
groups (see text). 
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Figure 1 shows the supine blood pressure, measured by sphygmomanometer 
and artenosonde and the bodyweight after treatment with placebos, and 
on treatment with sulindac and indomethacin compared to their preceed-
ing period of hydrochlorothiazide monotherapy. Addition of both NSAID 
to hydrochlorothiazide resulted only in slight changes of blood press­
ure, the most impressive change being an increase of 5/2 mm Hg after 
two weeks of treatment with indomethacin. After four weeks however 
blood pressure tended to revert to initial values. Furthermore body-
weight increased significantly on indomethacin, as compared to hydro­
chlorothiazide alone, whereas no significant change was observed during 
sulindac. 
During the final analysis, it appeared that both treatment sequence 
groups differed regarding their pretreatment bodyweight and their anti­
hypertensive response to hydrochlorothiazide. Therefore these groups 
were also analysed separately. Figure 2 depicts the supine blood press­
ure for these two groups. In one group hydrochlorothiazide induced a 
decrease of 17/11 mm Hg and in the other a decrease of 5/6 mm Hg, being 
a decrease of MAP of 10.0% and 5.30ί as compared to placebo values. A 
comparison of the response of blood pressure in both groups, when 
either indomethacin or sulindac was added, revealed small and similar 
changes within 3 to 5 mm Hg, being slightly greater in the group with 
the better response on hydrochlorothiazide alone. By contrast no signi­
ficant correlation could be establisned between this initial réponse on 
hydrochlorothiazide and the effect of either indomethacin (r = -0.43) 
or sulindac (г = -0.26) on MAP. Correlates between the effect of indo­
methacin and sulindac on MAP on one hand, and on the other bodyweight 
(r - 0.31 and г = -0.37 respectively), age (r = +0.05 and г = -0.07) or 
the increase of PRA on hydrochlorothiazide alone (r = -0.2 and г = 
-0.24) were not significant as well. Moreover a considerable variation 
was observed in effect of both NSAID on MAP without any consistent pat­
tern. 
Table 1 shows various biochemical parameters, as measured at the end of 
each treatment phase. Compared to placebo, hydrochlorthiazide induced a 
decrease of plasmapotassium (p < 0.01) and an increase of PRA (p < 
0.01). Addition of indomethacin attenuated these effects.By contrast 
sulindac did not influence in a statistically significant way these 
hydrochlorothiazide induced changes of potassium and PRA, although 
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нз 
К (mmol/l) 
PRA (ng/ml/h) 
Aldosterone 
(ng/100 ml) 
Creatinine 
( mol/l) 
UV Na + 
(nimol/24 h) 
UV K+ 
(nimol/24 h) 
N= 
3.74±0.34 3.22±0.30* 3.21±0.32 3.16±0.35* 3.44±0.31t 3 . 1 8 + 0 . 3 1 * 3.65+0.28 
1.36±0.B9 3.63±2.37* 2.62+2.09 3.04±1.80* 1.98±1.35t 2.60±1.64 1.50±1.5Θ 
12.4+8.7 15.1±10.2 13.9+7.8 15.5+8.05 19.1±14.5 19.5+12.1 12.3±12.2 
81.4±16.2 B2.2±17.1 84.5±15.5 79.5+18.2 83.5+20.5 79.5+17.6 
157±59 165+45 
72±31 
25 
80±33 
25 
163+48 158±56 
72+28 
25 
71 ±24 
25 
166+51 178±56 
75+27 
25 
70 ±24 
24 
78±13.6 
205±80 
68+31 
24 
means ± SD; * ρ < 0.01 compared to placebo;tp < 0.01 compared to preceeding Η. period 
Table 1 : Plasma potassium (K"1"), Plasma renin activity (PRA), Plasma aldosterone, serum creatinine and 
the 24h urinary excretion of sodium (UV Na"1") and potassium (UV K+), during treatment with placebos(P), 
hydrochlorothiazide 50 mg o.i.d. alone (H) and hydrochlorothiazide 50 mg o.i.d. in combination with 
indomethacin (I) 50 mg b.i.d. or sulindac (S) 200 mg b.i.d.. 
S 
Table 2 : Plasma potassium (K +), Plasma Renin Activity (PRA) and body weight (BW) during treatment with 
placebos (P), hydrochlorothiazide 50 mg o.i.d. alone and hydrochlorothiazide 50 mg o.i.d. in 
combination with indomethacin (I) 50 mg b.i.d. or sulindac (S) 200 mg b.i.d. in the two different 
treatment sequence groups (see text). 
Ρ HI S H2 I H3 Ρ 
Κ
+
 (mmol/l) 3.75+0.36 3.31+0.23* 3.27+0.27 3.15±0.30** 3 . 4 5 ± 0 . 2 3 t t 3.22+0.27** 3.72+0.37 
PRA (ng/ml/h) 1.36+0.86 4.18+2.52* 2.84+2.33 2.94±1.24 2.33+1.51 2.77+1.09 1.97+1.97 
BW (kg) 73.5±12.6 72.8±12.5 72.7±12.8 71.9+11.9 73.4+12.2t 70.7±11.0 71.5±11.6 
η = 11 11 11 11 11 10Δ 10 
p m ι H2 s нз ρ 
Κ+ (mmol/1) 3.74+0.33 3.16+0.39** 3.43+0.35 3.14+0.32** 3.13+0.36 3.15±0.34** 3.60±0.20 
PRA (ng/ml/h) 1.36±0.95 3.12+2.19* 1.70+1.18 3.19+2.23* 2.44±1.95 2.62+2.01 1.20+1.26 
BW (kg) 78.3±B.2 77.0+8.0 77.8±8.6 77.2±8.5 77.0±8.5 76.5±8.7 77.4+8.9 
η = 14 14 14 14 14 14 14 
tp < 0.05 ftp < 0.01 compared to preceeding H. period 
* Ρ < 0.05 ** ρ < 0.01 compared to placebo 
Mean ± SD 
Δ Bodyweight of patient withdrawn: 91 kg. 
птЫ/ 2Ah 
2 
16 
P G E a 
Δ 
Л, 
PGF2a 
I ι 
6 K e t o P G F 1 0 i 
Д, 
PL HUI I S PL HID I S 
Figure 3 Mean 24h urinary excretion (ng/24h) of PGE2, РСГга, 6 keto 
PGFia and thromboxane B2 (ТхВг) in 11 hypertensive patients 
after treatment for 4 weeks with placebos (PL), hydrochloro­
thiazide 50 mg 0.1.d. alone (H1) and hydrochlorothiazide 50 mg 
o.i.d. in combination with indomethacin 50 mg b.i.d. (I) or 
sulindac 200 mg b.i.d. (S). 
nmoi/2Ab -
ТхВз 
PGF2a 6Keto P G F i a 
Ι.H PL S.H U H PL S.H 
Figure H Individual values (mean of two samples) for the urinary excre­
tion of PGE2, PGF2a, 6 keto PGFia and tromboxane 82 (Тх г) of 
11 hypertensive patients after treatment for 4 weeks with pla­
cebos (PI) and with combined treatment with hydrochlorothia­
zide 50 mg o.i.d and indomethacin 50 mg b.i.d. (H+I) or sulin­
dac 200 mg b.i.d. (H+S). 
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the PRA fell also. No changes were observed for plasma aldosterone, 
serum creatinine and the 24h urinary excretion of sodium and potassium 
during treatment with neither hydrochlorothiazide alone nor hydrochlo-
rothiazide in combination with the NSAID. 
Table 2 gives the bodyweight, the plasma potassium and the PRA for both 
groups separately, showing the same tendencies i.e. that indomethacin 
blunts the hydrochlorothiazide induced decreases of potassium and body-
weight, and the increase of PRA, whereas sulindac in both groups caused 
a minor decrease of PRA. 
Figure 3 shows the mean 24h urinary excretions of PGE2, PGFjOi , 6 keto 
PGFia and thromboxane B2, during treatment with indomethacin and sulin-
dac compared to the first placebo and hydrochlorothiazide monotherapy 
phases and figure 4 shows the individual values. Both sulindac and 
indomethacin induced a decrease of the excretion of the PGs, with the 
exception of PGE2 (p < 0.1). Generally indomethacin tended to reduce 
the PGs more than sulindac, however the differences between the PG ex-
cretions during both NSAID were not significant. In addition no dif-
ferences were found between the PGs excretions during hydrochlorothia-
zide alone and placebo. 
DISCUSSION 
This study focussed on the problem of a possibly difference in inter-
action with hydrochlorothiazide between indomethacin and sulindac, as 
these two NSAID have been reported to exert distinct influences on the 
synthesis of renal prostaglandins¿l»5»9,10,22> Such a difference could 
have clinical consequences for the choice of an appropriate NSAID in 
hypertensive patients with concomitant rheumatic diseases e.g. osteo-
arthritis, when indomethacin blunts the blood pressure lowering effect 
of diuretics and sulindac does not, as is suggested in litera-
ture23»27. 
The results of the present study however do not support this opinion 
and confirm our previous data from and open triple crossover study in 
which neither indomethacin, nor naproxen or sulindac had a clear, con-
sistent effect on the blood pressure lowering action of hydrochloro-
thiazide. Like in that study we used a longterm prospective, crossover 
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design, measuring blood pressure with both a sphygmomanometer and an 
arteriosonde, providing for two and a mean of eight readings respecti­
vely, on each occasion. Again we found that neither indomethacin nor 
sulindac influenced in a clinically important way the antihypertensive 
effect of hydrochlorothiazide. At highest indomethacin induced a trans­
ient mild increase of mainly systolic blood pressure after treatment 
for two weeks. 
Fortuitously the two NSAID sequence groups had a different initial res­
ponse on hydrochlorothiazide and there was a difference in bodyweight. 
However when both groups were analysed separately, the effect of both 
NSAID on blood pressure appeared to be similar too i.e. a slight in­
crease in the group with the better response on hydrochlorothiazide and 
almost no effect in the group with the lower response. This may suggest 
that the interaction between NSAID and diuretics could depend of the 
response of blood pressure on diuretic treatment. However, we could not 
demonstrate a significant correlation between this response and the ef­
fect of both NSAID (r = -0.43 and г = 0.26 for the effects of indo­
methacin and sulindac respectively). In addition correlates between the 
influence of the NSAID on MAP and age, bodyweight or the increase of 
PRA on treatment with hydrochlorothiazide alone were not significant as 
well. 
Moreover a considerable variation of blood pressure was found on treat­
ment with both sulindac and indomethacin such as was observed previous­
ly by other investigators^? and our groupe. 
Although no differences between the NSAID on the blood pressure lower­
ing effect of hydrochlorothiazide could be established, indomethacin in 
contrast to sulindac, seemed to attenuate several other actions of the 
diuretic i.e. the decrease of bodyweight, and of plasma potassium and 
the increase of PRA. Sulindac induced a not significant decrease of 
PRA. These effects of both NSAID were found in the whole group and in 
both sequence groups separately and could be explained by a prostaglan­
din mediated inhibition of the release of renin"»"»'»''''»". Converse­
ly the alterations of plasma aldosterone and the urinary excretion of 
sodium and potasium were not statistically significant. However since 
none of these parameters was measured under standardized sodium and 
potassium intake, one has to be cautious to draw conclusions from this 
study regarding pathophysiological mechanisms. 
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A number of investigators have compared the effects of sulindac with 
other NSAID on renal prostaglandin synthesis^»5»22# in contrast to 
indomethacin'»22
 o r Ibuprofen^, sulindac appeared not to inhibit 
the synthesis of renal prostaglandins, whereas also no deleterious ef-
fects of that NSAID on kidney function were observed*. 
We found comparative effects of sulindac and indomethacin on renal 
prostaglandin synthesis, as reflected by the urinary excretion of pros-
taglandins1 . Both NSAID reduced the excretion of prostaglandins i.e. 
PGE2, PGF2a,6-keto PGFia and TXB2, only the decrease of PGE2 was 
not significant. In addition we found also no differences between the 
two drugs in their effect on kidney function, since no change of serum 
creatinine occurred on treatment with the NSAID. Our results differ 
from those of Ciabattoni et al*»5
 an(¡ other investigators22. How-
ever we treated the patients with sulindac during four weeks, in con-
trast to treatment periods of 3 to 7 days in the studies mentioned 
above. Moreover also the different patient groups, differences in 
dose' and prostaglandin assay could be responsible for the conflict-
ing data. Our results are in agreement with some recent published stu-
dies, in which generally similar effects were found both on urinary 
prostaglandins and renal function during treatment with indomethacin 
and sulindac'»19,20, 
In summary, it can be concluded from this study that there exists pro-
bably a difference between indomethacin and sulindac in interaction 
with the diuretic effect of hydrochlorothiazide, apparently however 
without clinically important impact on the long term antihypertensive 
action of hydrochlorothiazide. Whether this is caused by distinct ef-
fects on renal prostaglandin synthesis seems to be doubtful since a re-
duction of urinary prostaglandin excretion was found with both NSAID. 
SUMMARY 
In this double blind two period crossover study, we investigated the 
effect of indomethacin and sulindac on blood pressure in 25 hypertens-
ive patients being treated with hydrochlorothiazide. The study consist-
ed of seven four weeks periods. In the first and the last period the 
patients took placebos, in period two, four and six they were treated 
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with hydrochlorothiazide 50 mg o.i.d. alone, and in the third and fifth 
period hydrochlorothiazide 50 mg o.i.d. was given in combination with 
either indomethacin 50 mg b.i.d. or sulindac 200 mg b.i.d. in double 
blind random order. Blood pressure was measured measured by sphygmo­
manometer and arteriosonde, and bodyweight were determined every two 
weeks. 
Compared to placebo hydrochlorothiazide decreased the mean arterial 
pressure by B%. Addition of both indomethacin and sulindac resulted in 
only slight and generally similar changes of this blood pressure lower­
ing effect. This was found both for the whole group and when both 
treatment sequence groups were analysed separately. 
In contrast to sulindac, indomethacin attenuated the hydrochlorothia­
zide induced decreases of bodyweight, plasma potassium and the in­
crease of plasma renin activity. Both non steroidal antiinflammatory 
drugs (NSAID) reduced the 24h urinary excretion of prostaglandins (PCS) 
i.e. PGF2
a
, 6 ketoPGF-|
a
 and thromboxane B2 except PGE2. 
From this study it can be concluded, that in contrast to sulindac, in­
domethacin attenuated the diuretic action of hydrochlorothiazide, how­
ever apparently without consequences for its longterm blood pressure 
lowering effect. This study does not support the hypothesis that the 
difference between the two NSAID can be explained by different effects 
on renal PG synthesis. 
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CHAPTER 6 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF 
HYDROCHLOROTHIAZIDE IN PLASMA AND URINE 
Journal of Chromatography 1984; 307: 445-450. 
(With permission of the editor) 
INTRODUCTION 
Hydrochlorothiazide (HCTZ), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadia-
zine-7-sulfonamide, 1,1-dioxide is a potent diuretic drug, widely used 
in the treatment of systemic hypertension. 
Several methods to determine HCTZ in plasma and urine have been des­
cribed, e.g. in patient compliance studies. These methods include 
thin-layer chromatography , colonmetry , gas-liquid chromatography , 
and high-performance liquid chromatography (HPLC)5-10# 
о 
The method described by Tisdall et al. is suitable only for qualita­
tive determination of thiazide diuretics in urine. Other recent papers 
ц 1 Л 
on HPLC procedures , point out limitations of previously available 
methods. Each of the more recent methods, however, has disadvantages as 
Q 
well: in the method described by Soldin et al. , substantial amounts of 
interfering substances appear in the chromatograms of both serum and 
urine; the method described by Barbhaiya et al. requires different 
procedures for plasma and urine. 
For these reasons and because we needed to determine plasma and urinary 
HCTZ levels in a clinical trial, we developed a new, simple, rapid and 
sensitive HPLC method to measure HCTZ in plasma and urine, using chlo­
rothiazide (CTZ) as an internal standard. 
MATERIALS AND METHODS 
Reagents 
Ethyl acetate, acetic acid, sodium bicarbonate, tris(hydroxymethyl) 
aminomethane and methanol were obtained from Merck (Darmstadt, FRG). 
Anhydrous sodiLn acetate and tetrabutylammomum hydrogen sulphate were 
obtained from Baker Chemicals (Deventer, The Netherlands) and Janssen 
Chimica (Beerse, Belgium), respectively. All reagents were of analytic­
al grade quality. HCTZ and CTZ were kindly supplied by Merck, Sharp and 
Dohme (Haarlem, The Netherlands). 
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Human blood plasma stored at -2CPC was obtained from the local blood 
bank. Human urine (pH adjusted to 5.0 ± 0.5) was collected from a male 
volunteer shortly before analysis. 
^\p£aratus and £h£onia^g£a£h_ic_c£nditn)ns 
We used a Hewlett-Packard HP 1084B liquid Chromatograph equipped with a 
variable wavelength detector and autosampler. The detection wavelength 
was 272 nm. The stainless-steel column (15 cm χ 4.6 mm I.D.) was packed 
with LiChrosorb RP-18, particle size 5 μπι (Merck). The oven temperature 
was З^С and the injection volume was 10 μΐ for urine and 30 μΐ for 
plasma. 
The mobile phase was a mixture of methanol and twice-distilled water 
(20:80) containing 0.01024 M tetrabutylammonium hydrogen sulphate and 
0.00976 M tris(hydroxymethyl)aminomethane (pH 5.5). This was delivered 
at a rate of 1.2 ml/min, producing a pressure of 178 bars. 
The mobile phase was prepared as follows: 3.820 g of tetrabutylammonium 
hydrogen sulphate (mol. wt. = 339.54) were dissolved in 450 ml of 
twice-distilled water, and 1.363 g of tris(hydroxymethyl)aminomethane 
(mol. wt. = 121.14) were dissolved in 450 ml of twice distilled water. 
The latter solution was added to the tetrabutylammonium hydrogen sul­
phate until pH 5.5 was attained (429 ml were required). Next, the mix­
ture was filtered through a 0.45 μπι Millipore filter and 200 ml of 
methanol were subsequently added to 800 ml of the filtered mixture. 
Procedure 
We pipetted 100 μΐ of a solution of CTZ in methanol (50 mg per 100 ml 
methanol for urine, and 1 mg per 100 ml methanol for plasma) into a 
screw-capped extraction tube. The methanol was evaporated with a gentle 
stream of dry-filtered air, whereupon 0.5 ml of plasma (or urine), 0.5 
ml of 0.1 M acetate buffer (pH 3.8 for plasma and pH 5.0 for urine) and 
5 ml of ethyl acetate were successively pipetted into the tube. The 
tube was then closed and shaken mechanically for 30 min.; after centri-
fugation at 1300 g for 15 min. the organic layer was transferred to a 
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clean extraction tube containing 400 mg of sodium bicarbonate. 
The tube was closed again and placed on a whirl mixer for 20 sec. After 
centnfugation at 1300 g for 10 m m the organic layer was then pipetted 
into a clean tube and evaporated to dryness at 30° С with dry filtered 
air. Subsequently the residue was dissolved in 0.5 ml of the mobile 
phase (1 ml fore urine sample), and 30 μΐ (for plasma) or 10 μΐ (for 
urine) were injected onto the column. 
RESULTS 
Figs. 1 and 2 show typical chromatograms for blank plasma urine samples 
with or without sodium bicarbonate treatment, for plasma containing 
0.106 цд/ті HCTZ and 2.024 цд/ті CTZ and for urine containing 2.66 
μg/ml HCTZ and 1.012 μg/ml CTZ (both treated with sodium bicarbonate). 
The retention time of HCTZ is about 7.0 m m , and that of CTZ about 9.9 
m m . 
£аАсі!Л§.*і0Л 
The HCTZ concentration in a sample was determined by comparing the peak 
height ratio (HCTZ/internal standard) with a standard curve of peak 
height ratio versus HCTZ concentration. Whenever a sample containing 
HCTZ was measured, a standard curve was generated by adding different 
amounts of HCTZ to blank plasma or blank urine and analyzing them by 
the method already described. 
A linear relationship was found between the peak height ratio (PHR) of 
HCTZ to CTZ (Y) and the plasma HCTZ concentration (X), as given by the 
equation Y = 1.4117 X + 0.007 (г = 0.9997, η = 6) for the plasma HCTZ 
concentration range 0.025 - 1.00 μg/ml. For urine the equation was Y = 
0.03930 X + 0.00047 (г = 0.999Θ, η = 6) for the range 2.66 - 53.20 
μg/ml (internal standard concentration 101.2 μg/ml), and Y = 0.3703 X -
0.00183 (г = 0.9999, η = 5) for the range 0.25 - 5.39 μg/ml (internal 
standard concentration 10.12 μg/ml). 
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Recovery 
Overall recovery was determined by comparing the peak heights of HCTZ 
and CTZ obtained after injection of standard solutions with peak 
heights obtained after injection of extracted standard solutions (Table 
I). 
CTZ recovery from plasma was BO ± 4S at a concentration of 2.0 ^/ml 
and that from urine was 64 ± 2% at 50 μg/ml. 
TABLE I 
RECOVERY OF HCTZ IN PLASMA AND URINE 
η = 10 for all concentrations 
Plasma 
HCTZ cone 
Ug/ml) 
0.1 
0.3 
1.0 
:ent] :at ion Recovery 
(S) 
92 
95 
96 
C.V. 
(S) 
2 
H 
4 
Urine 
HCTZ concenti 
(цд/ті) 
0.5 
5.0 
15.0 
50.0 
rat: ion Recovery 
(S) 
95 
92 
88 
87 
C.V. 
(S) 
3 
3 
2 
1 
Sensitivit^ anà £Г^сіs_icm 
The detection limit with the analysis described was 0.025 цд/ті for 
plasma and 0.5 μg/ml for urine. Tables II and III show the within-day 
precision of HCTZ analysis in plasma and urine, respectively. The be­
tween-day precision for spiked HCTZ plasma samples (in the range 0.05 -
1.00 μg/ml) was 2.8% (n = 9 ) , and that for spiked HCTZ urine samples 
(in the range 5 - 5 0 μg/ml) was 1.6% (n = 6 ) . 
DISCUSSION 
As pointed out, none of the published methods to determine HCTZ met our 
requirements. Our method is simple and rapid, and does not require dif­
ferent procedures to measure HCTZ in plasma and in urine. 
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1 Chromatogram obtained f o r a blank plasma sample not t r e a t e d 
w i t h sodium bicarbonate ( I ) , f o r blank plasma t r e a t e d w i t h 200 
mg sodium b i c a r b o n a t e ( I I ) , and a sample c o n t a i n i n g 0.106 |^g/ml 
HCTZ and 2.024 μg/ml CTZ t r e a t e d w i t h sodium b i c a r b o n a t e ( I I I ) . 
5 10 15 
Time (mm) 
2 Chromatogram obtained for a blank urine sample treated with 400 
mg sodium bicarbonate (I), not treated with sodium bicarbonate 
(II), and a sample containing 2.66 μg/ml HCTZ and 1.012 μς/πιΐ 
CTZ, treated with sodium bicarbonate (III). 
TABLE II 
ANALYSIS OF SPIKED HCTZ PLASMA SAMPLES 
10 
10 
10 
10 
Θ.3 
2Λ 
3.7 
2.7 
10 
10 
10 
10 
2.2 
3.3 
2.0 
2.0 
Samples Concentration η C.V. 
1 0.021 
2 0.107 
3 0.320 
4 1.080 
TABLE III 
ANALYSIS OF SPIKED HCTZ URINE SAMPLES 
Samples Concentration η C.V. 
(μς/πιΐ) {%) 
1 0.51 
2 5.23 
3 15.46 
4 51.20 
Recovery of our internal standard, CTZ, is admittedly only about 70%; 
however, it is very constant. Like Cooper et al.b, we used sodi un bi­
carbonate. We found the HCTZ retention time in plasma to be constant 
after addition of sodium bicarbonate. For urine, we used sodium bicar­
bonate to eliminate interfering substances. 
Our method was applied in pharmacokinetic studies. As a typical example 
Fig. 3 shows the plasma concentration and urinary excretion of HCTZ in 
a healthy adult male volunteer after ingestion of one 50 mg tablet at 
.00 a.m. 
The fall in plasma concentration was biphasic, confirming results re-
11 12 
ported by others , . The elimination half-life is 4 h, and a peak 
plasma level is reached at 2 h. The other kinetic parameters were also 
within the reported range. 
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Plasma concentration 
( m g / l ) 
0.3-
0 . 2 
0.1 -
Urinary excretion 
( m g / hr) 
г З 
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12 16 
—ι 
20 24 
Time (hrs) 
Fig. 3 Plasma concentration (—) and urinary excretion ( ) of HCTZ in 
a healthy male volunteer, given 50 mg HCTZ orally. 
SUHWRY 
A high performance liquid chromatographic method for analysis of hydro­
chlorothiazide both in serum and urine is reported, using chlorothia­
zide as an internal standard. The drug is extracted into ethylacetate 
and treated with solid sodium bicarbonate. 
The detection limit is 0.025 μ9/πι1 for plasma and 0.5 μg/ml for urine; 
retention time for HCTZ is 7.0 m m and for CTZ 9.9 m m . Recovery of 
HCTZ from plasma is about 95% (CV 3S) and in urine 90% (CV Зй). 
Some results from a pharmacokinetic study are shown. 
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CHAPTER 7 
THE INFLUENCE OF INDOMETHACIN AND SULINDAC ON THE EFFECT AND ON 
KINETICS OF HYDROCHLOROTHIAZIDE IN HEALTHY VOLUNTEERS 
Accepted for publication in Clinical Pharmacology and 
Therapeutics 
INTRODUCTION 
In contrast to other non-steroidal anti-inflammatory drugs (NSAID) 
sulindac is supposed to have only minor effects on renal prostaglandin 
synthesis (7,8,15) and therefore might have kidney sparing properties 
(B). 
NSAID, such as indomethacin have been observed to blunt the antihyper-
tensive and sodium excretory effects of diuretic drugs, particularly in 
states of high angiotensine II levels (12,10,16) whereas sulindac has 
been found even to enhance the antihypertensive effects of thiazide 
diuretics in hypertensive patients (14). 
Beside dissimilar effects on renal prostaglandin synthesis, different 
influences of sulindac and indomethacin on pharmacokinetics of diure-
tics could also explain this apparently different interaction with diu-
retic drugs. Therefore we investigated the effect of short term treat-
ment with sulindac and indomethacin on the diuretic response upon 
treatment with hydrochlorothiazide and on hydrochlorothiazide pharmaco-
kinetics in eight healthy volunteers. 
MATERIALS AND fCTHODS 
The study was performed in eight healthy volunteers (four males, four 
females, age ranging from 26 to 39 years). All volunteers followed an 
open randomized cross-over protocol for 28 days, divided in four phases 
of one week each. During the whole period of four weeks the volunteers 
were treated with hydrochlorothiazide 50 mg/d, at day 8 and 22, indo-
methacin 25 mg t.i.d., or sulindac 200 mg b.i.d. for one week were 
added in random order. 
The subjects were requested to take hydrochlorothiazide at 8 h a.m., 
before breakfast, and to visit the outpatient clinic at the end of each 
treatment phase. On day 7, 14, 21, 28 voided urine was collected and 
venous blood samples were drawn, 0.5-1-2-3-4-8-10-24 h after ingestion 
of the tablet for determination of plasma and urine levels of hydro-
chlorothiazide, and in the first blood samples also sodium, potassium 
creatinine, hemoglobine, haematocrit, albumine and plasma renin activi-
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ty (PRA) were measured. The Ik h urinary excretion of sodium, potassium 
and creatinine were assayed in a sample collected on the day preceeding 
the visit to the outpatient clinic. 
Furthermore body weight was recorded; and the blood pressure was 
measured with a legally stamped sphygmomanometer both supine, after a 
ten minutes rest, and in the standing position. The volunteers used an 
unrestricted diet. Compliance was checked by tablet counting and came 
to 100%. Hydrochlorothiazide was determined in plasma and urine accor­
ding to the method described previously (11). The PRA was measured by 
radioimmunoassay (9). Areas under the curves (ADC) for hydrochlorothia­
zide plasma concentration were calculated according to the trapezoidal 
rule, time to peak hydrochlorothiazide concentration (Tmax), and the 
peak hydrochlorothiazide concentration (Cmax) were determined graphi­
cally. Renal clearance of hydrochlorothiazide was calculated as the 
ratio of the urinary excretion rate over mean plasma concentration 
during each urine collection period. 
Mean arterial pressure (MAP) was calculated as the sum of the diastolic 
blood pressure and one third of the pulse pressure. 
Statistical analysis was performed with Student t-test, and for the 
PRA, with Wilcoxon test. In the absence of significant differences be­
tween both hydrochlorothiazide monotherapy phases, the effects of both 
NSAID were compared with the values of the first period with hydrochlo­
rothiazide alone. 
The protocol was approved by the local ethic committee. 
RESULTS 
Table 1 shows the mean arterial pressure (MAP), the body weight and the 
various biochemical parameters, as measured at the end of the different 
treatment phases. Compared to baseline values, treatment with hydro­
chlorothiazide caused decreases of the body weight (p < 0.05) and the 
plasmapotassium (p < 0.05), whereas increases were observed for the PRA 
(p < 0.01), serum albumine (ρ < 0.01) the haematocrit (p < 0.05) and 
the 24 hr urinary excretion of sodium and potassium (p < 0.05). The 
changes of the MAP and the endogenous creatinine clearance (ECC) were 
not statistically significant. In addition comparison of the clinical 
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В HI НЗ I s u 
MAP 
BW 
К 
PRA 
ECC 
Albumine 
Hct 
79.8 ± 7.0 
63.5 ± 6.0 
4.1 + 0.21 
2.51 ± 12.8 
103.2 ± 1.05 
43.0 + 2.87 
0.40 ± 0.03 
78.6 ± 6.3 
62.8 ± 5.7* 
3.65 ± 0.52* 
5.32 ± 2.65** 
103.6 ± 20.7 
46.0 ± 2.93** 
0.43 ± 0.02* 
78.8 ± 5.6 
63.0 ± 6.0 
3.61 ± 0.36* 
4.38 ± 2.7 
103.2 ± 12.8 
45.4 ± 2.20* 
0.41 ± 0.03 
77.8 
64.1 
3.85 
1.51 
109.7 
43.6 
0.40 
± 5.3 
+ 6 . 1 t t 
± 0.2et 
± 0 . 7 6 t t 
± 20.5 
± 2.26t 
± 0.03t 
76.6 
63.4 
3.59 
4.21 
104.1 
44.8 
0.42 
± 5.2 
± 6.1 
± 0.2B 
± 2.34 
± 21.3 
± 2.12 
± 0.03 
mmHg 
kg 
m m o l / 1 
ng/ml/h 
ml/min 
g / i 
1/1 
Mean ± SO, *p < 0.05; **p < 0.01, compared to values before treatment, tp < 0.05; +tp < 0.01, compared 
to H1 
Table 1 Mean arterial pressure (MAP), mean body weight (BW), plasma potassium (K +), plasma renin acti­
vity (PRA), endogenous creatinine clearance (ECC), serum albumine, and haematocnt (Hct) in 
eight healthy volunteers treated with hydrochlorothiazide 50 mg/d alone for one (H1) and three 
(H3) weeks, or hydrochlorothiazide 50 mg/d combined with indomethacin 25 mg t.i.d. (I) or su-
lindac 200 mg b.i.d.(S) 
and biochemical parameters in the first and second treatment period 
with hydrochlorothiazide alone, revealed no statistically significant 
differences, although the effects as observed in the first period ap­
peared to be attenuated in the second. 
Compared to the values in the first period with hydrochlorothiazide 
alone body weight increased (p < 0.05), on treatment with indomethacin, 
whereas falls were noted for the PRA (p < 0.01), albumine (ρ < 0.05) 
and the haematocrit (p < 0.05). In contrast sulindac induced no statis­
tically significant alterations of these parameters, with the exception 
of a decrease of PRA (p < 0.05). Neither of the two NSAID affected the 
MAP, the ECC, or the 24 h urinary excretion of sodium and potassium in 
a statistically significant way. 
[HCTZ] plasma ( m g / l ) 
0.7 
[HCTZ] urine 
( m g / h r ) 
7 
Fig. 1 Mean plasma concentrations ( — ) (mg/1) and urinary excretion 
rate ( ) (mg/h) in eight healthy volunteers during treatment 
with hydrochlorothiazide alone for one (H1) and three weeks 
(H3) and hydrochlorothiazide 50 mg/d combined with indometha­
cin 25 mg t.i.d. (IND) or sulindac 200 mg b.i.d.(SUL) 
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Fig. 1 shows the mean plasma curves (mg/1) and the mean urinary excre-
tion rates (mg/h) as measured at the end of the four treatment phases. 
Mean ADC and Cmax during treatment with sulindac tended to be slightly 
higher than with indomethacin or with hydrochlorothiazide alone, but 
the differences were not statistically significant. However, two sub-
jects were found to have a remarkably higher AUC than than the other 
six (viz. 5.905 mg.l-1h and 5.312 mg.l-1h versus 2.377 0.66 m g . ! - ^ ) . 
These two volunteers had the lowest ECC of the whole group: 77 ml/min 
and 74 ml/min in contrast to a mean of 113±12 ml/min in the other six 
volunteers. 
Table 2 gives the course of the renal clearance of hydrochlorothiazide 
at seven measured intervals. Compared to the first hydrochlorothiazide 
monotherapy phase sulindac reduced hydrochlorothiazide renal clearance 
(p < 0.01) whereas no significant effects were found during indometha-
cin and in the second treatment phase with hydrochlorothiazide alone. 
Furthermore on sulindac the mean 24h urinary clearance of hydrochloro-
thiazide was significantly (p < 0.03), lower compared to the clearance 
in the first week with hydrochlorothiazide alone (13.5 ± 5.3 1/h versus 
18.0 ± 4.5 1/h). By contrast, comparison of the mean 24h renal clear-
ance of hydrochlorothiazide in the first week with that on indomethacin 
(17.1 ± 5.2 1/h) and during the second week with hydrochlorothiazide 
alone (15.9 ± 3.2 1/h) revealed no statistically significant differenc-
es. 
DISCUSSION 
In this study we investigated, whether two NSAID i.e. indomethacin and 
sulindac influenced the diuretic response on treatment with hydrochlo-
rothiazide in healthy volunteers and whether alterations of hydrochlo-
rothiazide pharmacokinetics might be responsible for the different in-
teraction of indomethacin and sulindac with diuretics, as reported in 
Literature (16,14). 
We observed that treatment with indomethacin in addition to hydrochlo-
rothiazide for one week, attenuated the hydrochlorothiazide induced de-
creases of body weight and plasma potassium in all eight volunteers and 
simultaneously decreased the PRA, the serum albumin, and the haemato-
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CLHCTZ HI 
нз 
1 n 
2 h 
3h 
4 h 
8h 
1 0 h 
2 4 h 
25.5 ± 
25.9 ± 
21.7 ± 
19.1 ± 
11.1 ± 
12.2 ± 
11.7 ± 
13.7 
10.3 
5.4 
4.4 
3.3 
2.4 
4.1 
16.4 ± 6.7 
26.7 ± 6.6 
21.4 ± 4.4 
18.2 ± 3.8 
10.4 ± 1.4 
10.9 ± 2.6 
7.1 ± 2.5 
18.2 ± 12.2 
24.8 ± 11.9 
23.1 ± B.6 
16.6 ± 7.2 
12.6 ± 3.7 
11.3 ± 3.9 
12.9 + 6.9 
14.6 ± 
17.6 ± 
17.7 ± 
14.3 ± 
9.6 ± 
11.3 ± 
8.6 ± 
11.3 
9.5 
6.4 
5.9 
3.3 
2.8 
2.9 
Mean ± SD, HI versus S ρ < 0.01; HI versus H3 not significant; HI versus I not significant 
Table 2 Mean renal clearance of hydrochlorothiazide (СІ-ц£у2) (1/h) in eight healthy volunteers calcu­
lated at 7 measured points during treatment with hydrochlorothiazide 50 mg/d alone for one (HI) 
and three weeks (H3) and on combined treatment with hydrochlorothiazide 50 mg/d and indometha-
cin 25 mg t.i.d. (I) or sulindac 200 mg b.i.d. (5). 
to 
ω 
crit. No statistically significant changes were found for the 24 h 
urinary excretion of sodium and potassium, probably, since sodium and 
fluid intake was unrestricted in this study. 
Furthermore we found no statistically significant effects of indometha-
cin on various pharmacokinetic parameters of hydrochlorothiazide inclu-
ding plasma AUC, Cmax, Tmax and on its renal clearance. The latter re-
sults are in agreement with those of Williams et al (17), who found 
also no effects on hydrochlorothiazide pharmacokinetics from addition 
of 100 mg indomethacin for three days to different dosages of hydro-
chlorothiazide. 
So our observations support indirectly the hypothesis that the attenua-
tion of the diuretic effects of thiazides by indomethacin results from 
pharmacodynamic mechanisms and, probably, it is a consequence of an 
indomethacin induced inhibition of renal prostaglandin synthesis 
(6,7,13). 
Conversely, sulindac is supposed to have only minor effects on renal 
prostaglandin synthesis (7,8,15). Indeed the drug showed in our study 
no statically significant effects on the diuretic action of hydrochlo-
rothiazide, with the exception of its effect on PRA. The hydrochloro-
thiazide induced increase of PRA however was attenuated by sulindac, 
but to a less degree than indomethacin did. 
By contrast, addition of sulindac appeared to reduce the renal hydro-
chlorothiazide clearance. As stated by Beerman in his reports on hydro-
chlorothiazide pharmacokinetics (2,3,4), calculation of the renal 
clearance of this diuretic within four hours after ingestion of the 
drug can lead to erroneous results, as equilibrium between blood and 
erythrocyte concentrations has not been reached in that time span. 
Therefore the values of the hydrochlorothiazide renal clearance should 
be considered with caution. Nevertheless sulindac turned out to di-
minish the renal clearance markedly and resulting in a mean, signifi-
cant, 23% decrease of the mean 24h renal clearance. This was not ob-
served for indomethacin. 
Since most of the diuretics can act only after they have reached the 
tubular lumen of the nephron, the diminishing of the renal clearance of 
hydrochlorothiazide resides probably on a blockade by sulindac of the 
tubular secretion of the diuretic, which has been reported in litera-
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ture also for other organic acids (5,6). However, the design of the 
study is not suitable to further elucidate this point. 
Although in this study the altered relationships between plasma and 
urine levels during sulindac did not lead to an important change of the 
diuretic effects of hydrochlorothiazide, it accounted probably for the 
remarkably higher hydrochlorothiazide plasma levels in two volunteers 
with a relatively smaller renal function. Furthermore, our observations 
could explain fairly well the results of Steiness et al (14) who found 
an enhancement of the antihypertensive effects of hydrochlorothiazide 
in hypertensive patients, concurrently treated with sulindac. For, on 
one hand the altered renal clearance of hydrochlorothiazide during su-
lindac probably provides for a more effective diuresis (5), whereas on 
the other hand vessel wall receptors might be stimulated more effective 
by the relative higher hydrochlorothiazide plasma concentrations. 
In conclusion, we found in healthy volunteers an attenuation of the ef-
fect of hydrochlorothiazide on treatment with indomethacin. No phar-
macokinetic interaction was observed between hydrochlorothiazide and 
indomethacin. By contrast, sulindac appeared to alter pharmacokinetics 
of hydrochlorothiazide i.e to diminish its renal clearance, apparently, 
however, with only minor effects on its diuretic action. Our data sug-
gest that beside distinct effects on renal prostaglandin synthesis, 
also pharmacokinetic factors should be considered to explain 
differences between sulindac and other NSAID. 
SUW1ARY 
We investigated the influence of two non steroidal anti-inflammatory 
drugs i.e. indomethacin and sulindac on the diuretic effect of hydro-
chlorothiazide and on hydrochlorothiazide pharmacokinetics in healthy 
volunteers. In an open randomized cross-over design eight healthy 
volunteers were treated with hydrochlorothiazide 50 mg o.i.d. for four 
weeks. In the second and fourth week indomethacin 25 mg t.i.d. or 
sulindac 200 mg b.i.d. were added. At the end of each week, blood 
pressure, body weight, plasmapotassium, creatinine, albumine, haemato-
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e n t , plasma renin activity (PRA) and the 24 h urinary excretion of 
sodium and potassiun were measured at the outpatient clinic. Further­
more plasmaconcentrations of hydrochlorothiazide and its urinary excre­
tion were determined 0.5-1-2-3-4-Θ-10-24 h after ingestion of the 
tablet. 
When indomethacin was added to hydrochlorothiazide an increase of body 
weight and plasmapotassium was observed whereas PRA decreased. Hydro­
chlorothiazide pharmacokinetics was not influenced. By contrast, sulin-
dac diminished the renal clearance of hydrochlorothiazide, and increas­
ed the hydrochlorothiazide plasmalevels in two subjects with a some­
what lower endogenous creatinine clearance. No pharmacodynamic inter­
action was found with the exception of a decrease in PRA. 
These results suggest that an interaction between indomethacin and 
hydrochlorothiazide is caused by pharmacodynamic mechanisms e.g. 
inhibition of renal prostaglandin synthesis, whereas sulindac may alter 
the renal clearance of hydrochlorothiazide. 
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CHAPTER 8 
DOES SULINDAC INFLUENCE THE KINETICS OF HYDROCHLOROTHIAZIDE? 
A SHORT TERM INTERACTION STUDY IN HYPERTENSIVE PATIENTS 
INTRODUCTION 
Conflicting data have been obtained from studies on the interaction of 
non steroidal antiinflammatory drugs (NSAID) with the blood pressure 
lowering effect of thiazides (Watkins et al 1980, Koopmans et al 
1984). Whereas some investigators found that certain NSAID e.g. indo-
methacin blunted the antihypertensive action of thiazides, this could 
not be confirmed by our group (Koopmans et al 1984) from studies in 
hypertensive patients, in which various NSAID were combined with hydro-
chlorothiazide. At highest, a transient attenuation of the antihyper-
tensive action of hydrochlorothiazide was observed. 
Furthermore, sulindac is a NSAID that seems to differ from other NSAID 
in interaction with thiazides (Steiness 1982). This may be a result of 
its lesser inhibitory effects on renal prostaglandins synthesis, as is 
suggested in literature (Ciabattoni et al 1980, Sedor et al 1984). 
Since contrasting data have been reported on that property of the drug 
as well, pharmacokinetic factors should be considered also to explain 
the different behaviour of sulindac compared to other NSAID, when com-
bined with thiazides. 
Indeed recently we observed in healthy volunteers (Koopmans et al 
1984) a diminishing of the renal clearance of hydrochlorothiazide by 
sulindac, when the drug was combined for one week with hydrochlorothia-
zide. By contrast, in that study, a decrease of the renal hydrochloro-
thiazide clearance was not observed with indomethacin, but this NSAID 
appeared to influence the diuretic action of hydrochlorothiazide more 
than sulindac. 
In the present paper we report on the results of short term combined 
treatment, of both NSAID with hydrochlorothiazide in hypertensive pa-
tients, to investigate their effects on the action and kinetics of 
hydrochlorothiazide. 
MATERIALS AND METHODS 
The study was conducted in eight patients with essential hypertension 
(three females, five males, age 53±10 years). Excluded were patients 
with secondary hypertension, signs or symptoms of congestive heart 
failure, aortic valve dysfunction, or a history of peptic ulcer dis-
ease. 
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The patients followed an open randomized cross over protocol for 28 
days, divided in four phases of one week each. During the whole period 
of four weeks the patients were treated with hydrochlorothiazide 30 mg 
o.i.d. alone, at day θ and 22, however, indomethacin 50 mg b.i.d. or 
sulindac 200 mg b.i.d. were added for one week in random order. Four of 
eight patients used diuretics chronically for hypertension treatment. 
The patients were requested to take hydrochlorothiazide at 8h a.m. 
and to visit the outpatient clinic at the end of each treatment phase. 
On day 7, H , 21, 28 voided urine was collected and venous blood sam­
ples were drawn at 0.5-1-2-3-4-8-10-24hrs after ingestion of the ta­
blet, for determination of plasma and urine concentrations of hydro­
chlorothiazide. In the first blood samples also sodium, potassium, 
creatinine, albumine, plasma renin activity (PRA) and aldosterone were 
measured. Furthermore at the visits to the outpatient clinic, body-
weight and supine blood pressure were recorded. The patients used an 
unrestricted diet. 
Blood pressure was measured with a legally stamped sphygmomanometer, 
supine, after a ten minutes rest. The mean of two readings was consi­
dered as the actual blood pressure, and Korotkoff V as the diastolic 
blood pressure. Hydrochlorothiazide levels in plasma and urine were de­
termined according to methods, described previously (Koopmans et al 
19B4). PRA and aldosterone were measured by radioimmunoassay (Drayer et 
al 1975, de Man 1980). Areas under the curves (AUG) for hydrochloro­
thiazide plasma concentration were calculated according to the trape­
zoidal rule, time to reach hydrochlorothiazide peak concentration 
(Tmax) and the peak hydrochlorothiazide concentration (Cmax) were de­
termined graphically. Renal clearance of hydrochlorothiazide was calcu­
lated as the ratio of the urinary excretion rate, over mean plasma con­
centration during the urine collection period. 
Mean arterial pressure (MAP) was calculated as the sum of the diastolic 
blood pressure and one third of the pulse pressure. 
To assess the degree of interaction between NSAID and hydrochlorothia­
zide, clinical and laboratory values during combined treatments were 
compared with values at the end of their preceeding phases with hydro­
chlorothiazide alone. Students t-test was used to determine statistical 
significance (p < 0.05), except for PRA and aldosterone (Wilcoxon 
test). 
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The protocol was approved by the local ethic committee. All patients 
gave an informed consent. 
RESULTS 
The complete values of one subject had to be excluded. The values of 
another patient, during the treatment period with indomethacin and its 
preceeding phase with hydrochlorothiazide alone, had to be excluded as 
well, since it appeared from the hydrochlorothiazide plasma concentra­
tions that the tablet was not taken at 8 a.m.. 
So there remained only six patients, who could be evaluated completely, 
and seven patients, in which the effect of sulindac could be analysed. 
On hydrochlorothiazide alone blood pressure dropped slightly from a 
pretreatment level of 151/93 ± 31/9 mm Hg to 143/93 ± 21/10 mm Hg after 
one week treatment and to a not significant different value of 143/92 ± 
20/10 mm Hg in the second week of monotherapy. The body weight decreas­
ed in these weeks from Θ3.2 ± 12.2 kg to 82.6 ± 12.1 kg and 82.1 ± 11.5 
kg respectively. The potassium dropped in the first week from 3.72 ± 
0.19 mmol/1 to 3.23 ± 0.44 mmol/1 (p < 0.05), and PRA rose from 1.95 ± 
2.25 ng/ml/h to 4.03 ± 1.68 ng/ml/h (p < 0.05). Aldosterone, the ECC 
and albumine did not change significantly on hydrochlorothiazide alone. 
Table 1 gives the mean blood pressure, MAP, body weight and various 
laboratory parameters, during combined treatment with hydrochlorothia­
zide and indomethacin or sulindac, with their respective preceeding 
values on treatment with hydrochlorothiazide alone. Compared to hydro­
chlorothiazide alone, blood pressure tended to rise on indomethacin and 
to fall on sulindac, however the differences were not significant. By 
contrast comparison of the blood pressure values on treatment with the 
two NSAID with each other, revealed a significant higher diastolic 
blood pressure with indomethacin (p < 0.05) than with sulindac. Both 
N5A1D attenuated significantly the decrease of body weight on hydro­
chlorothiazide alone and they reduced the PRA, however the decrease of 
PRA was only significant on indomethacin. Furthermore indomethacin 
tended to increase plasma potassium and sulindac to reduce it, result­
ing in significantly (p < 0.05) higher values of plasma potassium at 
the end of one week treatment with indomethacin, than on sulindac. 
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Blood pressure 
MAP 
Body weight 
K+ 
PRA 
Aldosterone 
ECC 
Albumine 
N = 
(mm Hg) 
(mm Hg) 
(Kg) 
(mmol/1) 
( n g / m l / h r ) 
(ng/100 ml) 
(ml/min) 
(g/D 
146/93±1B/10 
111±12 
81.4+13.0 
3.15+0.34 
4.19±2.8B 
10.8±7.7 
10β±29 
41.5+3.2 
6 
145/94* ±12/12 
111+11 
8 2 . 1 + 1 3 . O t t 
3.50+0.07Δ* 
1.68±1.18t 
9.4+5.22 
105±31 
41.0+1.09 
6 
142//92±23/11 
109+13.3 
82.0+11.5 
3.14+0.42 
7.00+6.5 
10.3+7.3 
109 ±28 
42.5±1.8 
7 
145/89±23/12 
108+13 
83.3±11.4tT 
3.0±0.34 
3.44+1.9 
10.8±7.3 
108+26 
41.1±3.3 
7 
mean ± SO, *p < 0.05 compared to S; Δρ < 0.1, tp < 0.05,ttp < 0.01 compared to Η 
Table 1 Blood pressure, mean arterial presure (MAP), body weight, plasma potassium (K +), plasma renin 
activity (PRA), aldosterone, endogenous creatinine clearance (ECC) and albumine in 7 hyper­
tensive patients treated with hydrochlorothiazide 50 mg o.i.d. (H) alone or combined with 
indomethacin 50 mg b.i.d. (1) or sulindac 200 mg b.i.d. (5) for one week. 
No significant alterations were observed of aldosterone, albumine or 
the endogenous creatinine clearance (ECC), although the fall of ECC on 
indomethacin combined with hydrochlorothiazide was borderline signifi-
cant (p = 0.05), compared to pretreatment values. 
Table 2 shows the pharmacokinetic parameters, as calculated from the 
hydrochlorothiazide plasma concentrations and the urinary excretion 
rate. No significant changes between the treatment phases were found 
for the Cmax, Tmax, the 24h urinary recovery, the AUC and the renal 
clearance of hydrochlorothiazide. 
C L H C T Z (l/h) 
30 
Figure 1 Individual 24h renal clearance of hydrochlorothiazide 
(CLHCTZ) (l/hr) in a group of hypertensive patients treated 
with hydrochlorothiazide 50 mg o.i.d. alone (H), or in com-
bination with sulindac 200 mg b.i.d. (H+S) or indomethacin 50 
mg b.i.d. (H+I). 
The figure gives the individual values for the mean 24h renal clearance 
on treatment with both NSAID compared to their preceeding period with 
hydrochlorothiazide alone. It shows, that a decrease of the clearance 
was found on sulindac in 5 of 7 patients, being a mean decrease of -9.3 
± 24% l/h, whereas on indomethacin this difference with its preceeding 
hydrochlorothiazide monotherapy phase was + 1.7 ± 34S l/h. In addition 
no significant differences were found between the 24h renal clearanc-
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AUC 
T
max 
Tm ax 
% excreted dose 
CLHCTZ o-*h 
CLHCTZ 4-Bh 
CLHCTZ e-2*h 
CLHCTZ 0-24h 
N = 
2.977±0.73 
0.354+0.09 
2.33+1.0 
66±11.4 
19.6±11.4 
10.2±3.6 
7.9±1.2 
14.7+6.θ 
6 
3.042±0.B4 
0.337±0.07 
2.08±1.1 
62.1±1.44 
17.θ±θ.2 
10.1±3.7 
9.0±4.21 
14.3±6.3 
6 
3.039+0.54 
0.325±0.06 
2.25+0.8 
67.3±10.3 
17.8±6.2 
9.2+2.3 
9.1+2.5 
13.9±3.8 
7 
3.263+0.81 
0.365+0.11 
2.14±0.9 
69.3±10.35 
15.0±8.0 
9.2±3.6 
10.1+4.0 
12.5±4.9 
7 
ng/ml.hr 
ng/ml 
hr 
mg/24hr 
1/hr 
l/hr 
1/hr 
l/hr 
means ± SD, no significant differences between the treatment phases. 
Table 2 Area under the hydrochlorothiazide plasma concentration curve (AUC), hydrochlorothiazide peak 
concentration (Cmax) time to reach peak concentration (Tmax), % excreted dose in 24h, renal 
clearance of hydrochlorothiazide (CIHCTZ^ l n ^ hypertensive patients treated with hydro­
chlorothiazide 50 mg o.i.d. (H) alone or combined with indomethacin 50 mg b.i.d. (I) or sulin-
dac 200 mg b.i.d. (S) for one week. 
h-» 
8 
es of hydrochlorothiazide in the first and the second week with hydro-
chlorothiazide alone, being 14.1 ± 6.0 1/h and 14.4 ± 4.9 1/h respect-
ively. 
DISCUSSION 
This study revealed a difference between indomethacin and sulindac in 
interaction with the blood pressure lowering effect of hydrochlorothia-
zide resulting in a significantly higher mean diastolic blood pressure 
value after one week of concurrent therapy with indomethacin, as com-
pared to sulindac. This different interaction of the NSAID was observed 
despite a limited initial fall of blood pressure on hydrochlorothiazide 
alone, which should probably due firstly, to the short treatment pe-
riod of one week, and secondly to the fact that 3 of 7 patients used 
already diuretics chronically. 
The finding of a different influence of the two NSAID on blood pressure 
may in agreement with the hypothesis of distincts effects on renal 
prostaglandins synthesis (Ciabattoni 1980, Sedor et al 1984) which may 
be even supported by the greater decrease of PRA during indomethacin 
(Freeman 1984, Clive 1984), than on sulindac. By contrast in a previous 
study we found already the interaction of NSAID with the blood pressure 
lowering effect of hydrochlorothiazide to be transient and of minor 
clinical importance (Koopmans et al 1984), when NSAID are given to 
hydrochlorothiazide treated hypertensive patients for a longer period. 
Moreover both NSAID appeared to have sodium retaining properties, for 
an equal increase of bodyweight was observed. All these observations 
may plead for a more complicate mechanism as an explanation for the 
different properties of the two NSAID. 
Therefore a pharmacokinetic explanation was sought. Sofar no pharmaco-
kinetic interaction has been established between indomethacin and thia-
zides (Williams et al 1982, Dusing et al 1983). By contrast we found in 
healthy volunteers (Koopmans et al 1984) a striking diminishing of the 
renal clearance hydrochlorothiazide when sulindac was added. 
In this study however, we could not establish statistically significant 
alterations of several pharmacokinetic parameters including Cmax, Tmax, 
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24h urinary excretion, AUC, or the renal clearance of hydrochlorothia­
zide. Anyhow, the AUC's tended to increase, when sulindac was added and 
in 5 of 7 patients the 24h renal hydrochlorothiazide clearance decreas­
ed on sulindac, compared to values on hydrochlorothiazide alone. In ad­
dition a comparison of the influences of both NSAID on the mean 24h re­
nal clearances of hydrochlorothiazide revealed a decrease of -9% (±24 
1/h) on sulindac and an increase of +2 % (± 34 1/h) on indomethacin, 
suggesting that the effects of sulindac on renal hydrochlorothiazide 
clearance may be greater than those of indomethacin. 
On the other hand, it cannot be excluded, that changes of intrarenal 
hemodynamics due to a decrease of blood pressure or perhaps due to the 
chronic use of diuretics (Carvalho 1978, Danielson 1984), may be res­
ponsible for the fact that the alterations of the renal hydrochloro­
thiazide clearance in these hypertensive patients, are less clear com­
pared to the changes seen in healthy volunteers. 
In summary in this short term study we found distinct effects of indo­
methacin and of sulindac and on blood pressure and plasma potassium, 
and similar influences on bodyweight. These data do support indirectly 
our previous results, in which transient influences of NSAID on blood 
pressure were observed. Our pharmacokinetic data suggest, that, in 
agreement with a study in healthy volunteers,also different influences 
on renal hydrochlorothiazide clearance should be considered to explain 
the different interaction with hydrochlorothiazide of indomethacin and 
sulindac, and not only different inhibitory effects on renal prosta­
glandin synthesis. 
ЯІЖАНУ 
We investigated, the influence of indomethacin and sulindac on the 
action and kinetics of hydrochlorothiazide in patients with essential 
hypertension. Eight patients with essential hypertension, 4 of 8 being 
treated chronically with diuretics, were treated for four weeks with 
hydrochlorothiazide 50 mg o.i.d.. In week 2 and 4 was added either 
indomethacin 50 mg b.i.d. or sulindac 200 mg b.i.d. each for 1 week. At 
the end of each week blood pressure, bodyweight, plasma potassium, 
creatinine, albumine, haematocrit, plasma renin activity (PRA), aldos-
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terone were measured. Furthermore plasma concentrations of hydrochloro-
thiazide and its urinary excretion rate were determined 0.5-1-2-3-4-8-
10-24h after ingestion of the tablet. One patient dropped out. 
When added to hydrochlorothiazide both indomethacin and sulindac induc-
ed an increase of bodyweight, and diastolic blood pressure and plasma 
potassium were significantly higher after treatment with indomethacin 
compared with sulindac. Furthermore indomethacin lowered PRA. No sta-
tistically alterations were found of Cmax, Ttnax, AUC and 24h urinary 
excretion and the renal clearance of hydrochlorothiazide, when both non 
steroidal antiinflammatory drugs (NSAID) were added to hydrochlorothia-
zide. However sulindac lowered the renal clearance of hydrochlorothia-
zide in 5 of 7 patients and generally tended to influence the renal 
clearance of hydrochlorothiazide more than indomethacin. The study 
shows that indomethacin and sulindac differ in effect on blood pres-
sure, when short term added to hydrochlorothiazide and that one should 
take into account pharmacokinetic factors to explain this difference. 
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CHAPTER 9 
THE INFLUENCES OF IBUPROFEN, DICLOFENAC AM) SULINDAC ON THE BLOOD 
PRESSURE LOWERING EFFECT OF HYDROCHLOROTHIAZIDE 
INTRODUCTION 
Recently we have reported on the results of two studies, in which we 
added naproxen, indomethacin or sulindac to hydrochlorothiazide in pa­
tients with mild to moderate essential hypertension^|2. in contrast 
to data of other investigators^ιΌ»we could not demonstrate an in­
teraction of these three non steroidal antiinflammatory drugs (NSAID) 
with the chronic antihypertensive action of hydrochlorothiazide, des­
pite an attenuation of other effects of the drug. 
Furthermore our studies indicated that differences in interaction be­
tween sulindac and indomethacin on one hand, and the diuretic action of 
hydrochlorothiazide on the other, could not be fully explained by dif­
ferences in effects on the renal synthesis of prostaglandins, as is 
suggested in literature6,7,8,9
> 
To investigate, whether the absence of an attenuation of the blood 
pressure lowering action of hydrochlorothiazide holds also for other 
NSAID, we compared the effects of addition of sulindac to hydrochloro­
thiazide in hypertensive patients, with those of Ibuprofen and diclo­
fenac, two other NSAID that have been shown to inhibit renal prosta­
glandin synthesis^Oni. 
WTERIALS AND fCTHODS 
Nine patients (5 females, 4 males) age 21-65 years (mean 50.5 ± 9.1 
years) with essential hypertension selected from the outpatient clinic 
entered the study. Included were patients with an untreated supine dia­
stolic blood pressure higher than 85 mm Hg and lower than 120 mmHg. 
None of the patients had secondary hypertension, signs or symptoms of 
congestive heart failure, aortic valve dysfunction or a history of pep­
tic ulcer. All patients gave an informed consent and the local ethic 
committee approved the protocol. 
The study was designed as an open triple cross over trial of 28 weeks. 
After a washout period of 4-8 weeks in which all other antihypertensive 
medication was discontinued, treatment was started with hydrochloro­
thiazide 50 mg o.i.d., then after 4 weeks in random sequence, either 
sulindac 200 mg b.i.d., Ibuprofen 400 mg t.i.d. or diclofenac 25 mg 
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t.i.d. were added for 4 weeks in random sequence, and always with an 
in-between washout period of 4 weeks, in which hydrochlorothiazide 
alone was continued. 
Every 2 weeks the patients visited the outpatient clinic for measure-
ment of supine blood pressure and body weight. Every 4 weeks a venous 
blood sample was drawn for determination of electrolytes, serumcreati-
nine, albumine, plasma renin activity (PRA) and plasma aldosterone. 
Furthermore the patients were requested to collect 24h urine for deter-
mination of the excretion of sodium, potassium and creatinine, at the 
end of each treatment period. 
The blood pressure was measured in the supine patient on the right arm 
at two minutes intervals during 25 minutes, using the arteriosonde 
1217. For evaluation means of all readings were calculated, with omit-
tance of the first and and the last two readings. At the end of the 
automatic measurements two blood pressure readings were determined with 
a legally stamped sphygmomanometer (Erkameter 300) on the left arm, 
also in the supine position. Fase V of the Korotkoff sounds was consi-
dered as the diastolic blood pressure. The mean arterial pressure (MAP) 
was calculated as the sum of the diastolic blood pressure and one third 
of the pulse pressure. 
Patient compliance was checked by two weekly pill counts and came to a 
mean of 98.4 ± 2.9% for hydrochlorothiazide (range 89-100), 98.3 ± 2.7% 
for Ibuprofen (range 92-100), 97.7 ± 4.1Ä for sulindac (range 88-100) 
and 97.5 ± 3.5Й for diclofenac (range 91-100). 
Plasma aldosterone and PRA were determined by radioimmunoassay^,13# 
To asses the degree of interaction between NSAID and hydrochlorothia­
zide, blood pressure, bodyweight and laboratory parameters during com­
bination treatment were compared to values at the end of their preceed-
ing periods with hydrochlorothiazide alone. Student t-test for paired 
data was used to demonstrate statistical significance, except for PRA 
and aldosterone (Wilcoxon test for paired data). Ρ < 0.05 was consider­
ed to be statistically significant. Results are presented as means ± 
SD, unless indicated otherwise. 
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RESULTS 
Originally 11 patients were selected, in order to complete 9 patients 
the study. However, 2 patients did not enter, since diastolic blood 
pressure grew higher than 120 mm Hg in the washout phase.One patient 
dropped out from the study. This patient developed an attaque of gout 
after two weeks of treatment with hydrochlorothiazide alone. The re­
maining eight patients completed the study. 
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Figure 1 Supine blood pressure, measured by sphygmomanometer (Erka­
meter) and arteriosonde, and body weight before treatment 
(B), after four weeks of combined treatment with hydrochloro­
thiazide 50 mg o.i.d. and ibuprofen 400 mg t.i.d. (IBU) or 
sulindac 200 mg b.i.d. (SDL) or diclofenac 25 mg t.i.d. 
(DICL) and at the end of their preceeding periods of treat­
ment with hydrochlorothiazide 50 mg o.i.d. alone (H). 
After four weeks of treatment blood pressure, measured by sphygmomano­
meter, dropped from a (mean ± SD) pretreatment level of 147/101 ± 17/Θ 
mm Hg to 143/100 + 1Θ/Θ mm Hg. After 12 weeks however a further de­
crease was observed to 134/97 + 8/10 mm Hg, and then stabilised within 
2 à 3 mm Hg in the third and fourth period. The same tendency was found 
114 
в HI Н2 нз m 
BP supine (mm Hg) SPH 118+12 114±11 109±8* 109±10* 109±11 
ART 116±8 111±B* 108±9 107+15 109+11 
BW (kg) 72.9 ± 14.5 72.3 + 14.2* 72.4 ± 14.3 73.1 ± 14.6 t 73.1 ± 14.8 
Mean ± SD, * ρ < 0.05, as compared to pretreatment values, tp < 0.05, compared with H2. 
Table 1 Mean arterial pressure (MAP) measured by sphygmomanometer (SPH) and arteriosonde (ART), and 
body weight (BW) in the subsequent four periods, on treatment with hydrochlorothiazide 50 mg 
o.i.d. alone (H), and at the start of the study (B). 
СЛ 
for the blood pressure, measured by artenosonde. Bodyweight decreased 
with 0.6 kg after four weeks of treatment with hydrochlorothiazide, and 
tended to rise slightly in the subsequent periods. The mean arterial 
pressure (MAP) and the bodyweight during the four subsequent treatment 
phases with hydrochlorothiazide alone, are shown in table 1. 
Figure 1 shows the mean supine blood pressure (± SEM) as measured with 
sphygmomanometer (Erkameter), artenosonde and bodyweight after 4 weeks 
of treatment with the three NSAID, compared with blood pressure at the 
end of their preceeding periods of monotherapy with hydrochlorothia-
zide. Compared to its preceeding hydrochlorothiazide phase, Ibuprofen 
induced a increase of systolic blood pressure, which reached statistic-
al significance after 4 weeks of treatment (p < 0.05), however this was 
observed only for the sphygmomanometer measurements. No significant 
alterations were found for the diastolic blood pressure on Ibuprofen 
and for both systolic and diastolic blood pressure on sulindac and di-
clofenac, although a slight increase of systolic blood pressure during 
the treatment with the latter NSAID was found as well. 
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Figure 2 Mean arterial pressure (MAP) and the percentual change of 
body weight (BW) in eight hypertensive patients at the end of 
four weeks of combined treatment with hydrochlorothiazide 50 
mg o.i.d. and Ibuprofen 400 mg t.i.d. (1BU), or sulindac 200 
mg b.i.d. (SUL), or diclofenac 25 mg t.i.d. (DICL), compared 
with values at the end of their preceeding periods with 
hydrochlorothiazide 50 mg o.i.d. (H4) alone. 
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Table 2 Plasma potassium (K +), serumcreatinine, plasma renin activity (PRA), aldosterone, albumine, 
haematocnt, and the 24h urinary excretion of sodium (UV
na
+) and potassium (UV^+j before 
treatment (B), during combined treatment with hydrochlorothiazide 50 mg o.i.d. and Ibuprofen 
400 mg t.i.d. (IBU), or sulindac 200 mg b.i.d. (SUL), or diclofenac 25 mg t.i.d. (DICL) and 
with their preceeding period of treatment with hydrochlorothiazide 50 mg o.i.d. alone (H). 
IBU SUL DICL 
K+ 
C r e a t . 
PRA 
A l d o s t . 
Album. 
Hct 
UVNa+ 
UVK+ 
3.β0±0.17 
74.6±14.6 
1.13+1.03 
θ.5±4.8 
40.5±4.11 
0.411±0.03 
137+59 
67+41 
3.20±0.26** 
80.8±14.3 
3.72±2.73** 
11.8±5.2 
40.8±4.4 
0.422+0.03 
166+47* 
73±25 
3.33±0.42 
78.0±12.8 
2.77±2.8t 
7.1+3.8 
40.8±4.2 
0.407±0.03 
160±75 
64 ±40 
3 . 2 6 ± 0 . 3 1 * * 
78.4+12.В 
3.68±2.76** 
11.3±7.13 
40.0+4.2 
0.415±0.03 
140±46 
61 ±30 
3.15±0.36 
81.3+14.6 
3.89+3.24Δ 
11.8±5.6Δ 
40.4±4.7 
0.417+0.03 
180 ±59 Δ 
61±29Δ 
3.33±0.24* 
81.4±10.5Δ 
3.47±2.50** 
14.0±6.8 
40.6±5.2 
0.426±0.03 
209 ±110* 
69 ±41 
3.34±0.34 
8 4 . U 1 7 . 4 
3.30+3.0 
10.9±5.5 
40.6±3.4 
0.422±0.02 
142+48 
61 ±27 
mmol/1 
mol/1 
ng/ml/h 
ng/100ml 
g / i 
1/1 
mmol/24h 
mmol/24h 
Mean ± SD, *p < 0.05, **p < 0.005, compared to B, tp < 0.05, compared to Η, Δη = 7 
By contrast body weight showed statistically significant increases af­
ter two weeks of treatment with all three NSAID, particularly with Ibu­
profen (ρ < 0.005) and diclofenac (p < 0.005) and to a lesser degree 
with sulindac (p < 0.05). At four weeks significant differences as com­
pared to values on hydrochlorothiazide alone, remained for body weight 
during treatment with both Ibuprofen (ρ < 0.005) and diclofenac (p < 
0.005), but disappeared on treatment with sulindac (p < 0.07). 
Figure 2 depicts the individual values for the changes of the MAP 
(measured by sphygmomanometer) and the body weight after 4 weeks of 
treatment with the NSAID, compared to the values at the end of the pre-
ceeding phase with hydrochlorothiazide alone. It illustrates the indi­
vidual variation in response of the MAP, compared to the far our more 
consistent pattern of the alteration of the body weight. 
Table 2 gives various biochemical parameters, as measured at the end of 
each period of combination treatment and their preceeding period with 
hydrochlorothiazide alone, compared to values at the start of the stu­
dy. Compared to pretreatment values, hydrochlorothiazide alone induced 
a decrease of potassium and an increase of PRA. Alterations of aldos­
terone, serumcreatinine, haematocnt, albumine and the 24h urinary ex­
cretion of sodium and potassium were not significant. Addition of the 
NSAID induced no significant changes of any of the biochemical values, 
with the exception of a decrease of PRA on Ibuprofen treatment. 
DISCUSSION 
In this study we found further evidence, that the addition of NSAID to 
hydrochlorothiazide does not affect in a clinically important way its 
antihypertensive action. Like in a former study we used the triple 
cross-over design, with seven four weeks periods. Periods of four weeks 
were chosen, firstly, since this has been shown to be sufficiently long 
to demonstrate an interaction between the drugs'>^>5, secondly to 
prevent carry over effects, and thirdly to reveal possibly transient 
effects'! >2, Furthermore we used dosages, common in clinical practice. 
With this design we found only a slight alteration of the MAP on treat­
ment with all three NSAID, although admittedly, the number of patients 
was small. The only statistically significant change of blood pressure 
was an increase of systolic blood pressure on treatment with Ibupro­
fen. However this could be demonstrated only for blood pressure, 
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measured by sphygmomanometer and not for the arteriosonde readings. 
Therefore one should be cautious to draw conclusions from this increase 
of blood pressure. In addition it should be stressed that the arterio­
sonde value is a mean of eight readings on each occasion, and further­
more this blood pressure measurement method is blind, which may compen­
sate for a disadvantage of the study i.e. the open character. 
In agreement with previous data of both our groupe and other investiga­
tors·', we found a considerable variation in response of blood pressure, 
on treatment with all three NSAID without any consistency. 
In contrast to the blood pressure data, statistically significant al­
terations were found for the bodyweight. Both Ibuprofen and diclofenac 
induced statistically significant increases of bodyweight. On the other 
hand the increase of body weight on sulindac was less, and appeared 
to be transient, for after four weeks body weight tended to decrease to 
its pretreatment level. The observations on the effect of Ibuprofen and 
diclofenac on body weight, are in accordance with literature on sodium 
retaining properties of NSAID, due to inhibition of renal prostaglan­
dins synthesis^n5»<6,l7# Furthermore they agree with our results 
from the addition of indomethacin and sulindac to hydrochlorothiazide 
treated hypertensive patients, who showed increases of bodyweight on 
indomethacin and no significant alterations on sulindac^»^. 
From the various laboratory parameters determined at the end of each 
treatment phase, only PRA decreased significantly on treatment with 
Ibuprofen, fitting in the hypothesis of a prostaglandin induced inhibi­
tion of the release of renin'' * » 15. In agreement with data of our, and 
of other groups, sulindac had no influence on PRA''»^. Conversely one 
could expect such a PRA decrease for diclofenac as well^, but this 
could not be established, whereas also no alterations were found for 
aldosterone and potassium during both Ibuprofen and diclofenac. However 
because of the limited number of patients in this study, one has to be 
careful to draw conclusions on this point. 
Finally no special kidney sparing effect could be demonstrated for su­
lindac" И ' as compared to Ibuprofen and diclofenac, since alterations 
of serum creatinine were slight and generally similar on treatment with 
all three NSAID. 
Therefore the main conclusion of this study is, that, although there 
may exist differences in interaction with the sodium excreting proper-
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ties of hydrochlorothiazide, between sulindac on one hand, and Ibupro­
fen and diclofenac on the other, this interaction probably has no cli­
nically important consequences for the chronic blood pressure lowering 
effect of the drug. 
SUKMARY 
In an open triple crossover study in eight patients with essential 
hypertension, we investigated, whether the blood pressure lowering ef­
fect of hydrochlorothiazide 50 mg o.i.d. is attenuated, if Ibuprofen 
400 mg t.i.d., diclofenac 25 mg t.i.d. or sulindac 200 mg b.i.d. are 
added for 4 weeks. We found slight, statistically not significant, 
changes of mainly systolic blood pressure, with the exception of a sta­
tistically significant increase of systolic blood pressure after 4 
weeks of treatment with Ibuprofen. However this was found only for 
blood pressure, measured by sphygmomanometer, and not for blood press­
ure, measured with an arenosonde. Furthermore significant increases of 
bodyweight were found on treatment with both Ibuprofen and diclofenac, 
whereas the increase of bodyweight on sulindac was less, and trans­
ient. No statistically significant changes were found for various bio­
chemical parameters, including plasma electrolytes, plasma renin acti­
vity (PRA), aldosterone, albumine, creatinine, haematocnt and the 24h 
urinary excretion of sodium and potassium with the exception of a de­
crease of PRA on Ibuprofen. From these observations, it is concluded 
that Ibuprofen and diclofenac appear to differ from sulindac in inter­
action with the diuretic action of hydrochlorothiazide, however, with­
out consequences for its longterm antihypertensive action. Apparently 
all three non steroidal antiinflammatory drugs can be combined safely 
with hydrochlorothiazide in hypertensive patients. 
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CHAPTER 10 
SUMMARY AND CONCLUSIONS 
This study focused on two main questions. Firstly we investigated 
whether non steroidal antiinflammatory drugs (NSAID) might blunt the 
blood pressure lowering effect of hydrochlorothiazide in patients with 
essential hypertension. Secondly we investigated, whether sulindac dif-
fers from other NSAID in interaction with the effects of hydrocholoro-
thiazide, and whether this could be due to a different influence of su-
lindac on renal prostaglandin synthesis. Finally we investigated, 
whether pharmacokinetic factors are involved in the interaction between 
hydrochlorothiazide on one hand and sulindac or indomethacin on the 
other. 
- Do NSAID blunt the blood pressure lowering effect of hydroahloro-
thiazide? 
CHAPTER 2 comprises a review of data from the literature on the inter-
action between NSAID and diuretics, in healthy volunteers and in 
several clinical conditions, usually requiring diuretic treatment. 
NSAID have been shown to blunt particularly the action of loop diure-
tics both in healthy volunteers and in edematous states e.g. congestive 
heart failure. In such circumstances NSAID have also been demonstrated 
to affect kidney function. By contrast no consistent interaction has 
been demonstrated between NSAID and distally acting diuretics, and par-
ticularly with respect to the antihypertensive effect of thiazides the 
data in literature are both scarce and controversial. The inhibitory 
effects of NSAID on renal prostaglandins are probably the underlying 
mechanism for the interaction of these drugs with diuretics, but others 
have also been suggested. 
We have conducted 3 long term studies, to investigate whether NSAID 
attenuate the blood pressure lowering effect of hydrochlorothiazide. 
CHAPTER 3 describes the results of an open triple cross over trial, in 
which in random sequence, either indomethacin, sulindac or naproxen 
were added for four weeks to ten patients with essential hypertension 
already treated with hydrochlorothiazide. After two weeks of combina-
tion treatment, only indomethacin induced a slight increase of blood 
pressure, and a significantly higher blood pressure than sulindac and 
naproxen. But after four weeks of treatment with all three NSAID no 
statistically significant alteration of the hydrochlorothiazide induced 
decrease of blood pressure was found. 
124 
The results of this study are confirmed by those of CHAPTER 5. In this 
randomized double blind placebo controlled study, either indomethacin, 
or sulindac were administered for four weeks to 25 patients with essen-
tial hypertension, treated with hydrochlorothiazide. Again after two 
weeks a slight increase of blood pressure was observed, when hydrochlo-
rothiazide was combined with indomethacin, however, after four weeks of 
combination treatment blood pressure differed not significantly from 
that on hydrochlorothiazide alone. Furthermore, since in this study, 
the two sequence groups had a different initial response on hydrochlo-
rothiazide, both groups were analysed separately. In the group with the 
larger response on hydrochlorothiazide both indomethacin and sulindac, 
induced a slight and similar increase of blood pressure, whereas in the 
group with the smaller response, there was hardly any change of blood 
pressure, when the NSAID were added. This suggests that the degree of 
interaction between NSAID and diuretics may depend on the degree of 
blood pressure fall on the diuretic alone. However, a significant cor-
relation between the initial response of blood pressure on hydrochloro-
thiazide and the effect of both NSAID could not be demonstrated in this 
study. 
CHAPTER 9 reports on the results of four weeks addition of either Ibu-
profen, diclofenac, or sulindac to hydrochlorothiazide, in 8 patients 
with essential hypertension. Only Ibuprofen increased (systolic) blood 
pressure significantly, but this finding could be established only for 
the measurements with the sphygmomanometer. 
Therefore it can be concluded, that NSAID appear not to influence the 
blood pressure lowering action of hydrochlorothiazide, when given con-
currently. There may be a transient increase of blood pressure, but at 
long term this interaction subsides. Only Ibuprofen realised a rise in 
blood pressure still lasting at week four, but the number of patients 
is too small to draw definite conclusions with regard to this NSAID. 
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Does sulindac differ from other NSAID in interaction with the 
effect of hydrochlorothiazide? 
Generally spoken the reported findings indeed support the conclusion 
that sulindac interacts differently with hydrochlorothiazide in compa-
rison with the other NSAID. 
CHAPTER 8 reports on the results of a study in which sulindac or indo-
methacin were added for one week to hydrochlorothiazide. At the end of 
this week diastolic blood pressure was significantly lower on sulindac, 
when compared to indomethacin. The same was found in CHAPTER 3, but, as 
outlined above, on chronic treatment no differences could be demon-
strated between the influence of sulindac on blood pressure and those 
of other NSAID. 
Conversely more impressive differences between sulindac and other NSAID 
were observed with regard to other effects of hydrochlorothiazide. When 
indomethacin was added to hydrochlorothiazide, the diuretic induced de-
crease of body weight was attenuated in four studies (CHAPTER 3,5,7,8) 
and the same holds for Ibuprofen and diclofenac (CHAPTER 9). 
Furthermore, indomethacin tended to blunt the decrease of plasma potas-
sium and the increase of plasma renin activity (PRA), both in hyper-
tensive patients and in healthy volunteers (CHAPTER 3,5,7,8). 
By contrast sulindac induced no significant alterations of bodyweight, 
when the drug was administered for four weeks to hypertensive pa-
tients (CHAPTER 3,5). However, when 8 patients were treated for one 
week body weight increased (CHAPTER 8), whereas elsewhere also a 
transient increase was observed (CHAPTER 9). These data suggest that 
sulindac differs particularly from indomethacin, but also from other 
NSAID in its effect on body weight. Moreover sulindac appeared to dif-
fer in effect on several biochemical parameters. Whereas indomethacin 
tended to increase plasma potassium always, sulindac tended to reduce 
it (CHAPTER 3,5,8) after treatment for one week even leading to signi-
ficant differences between the potassium on indomethacin and on sulin-
dac, combined with hydrochlorothiazide (CHAPTER 8).In addition also the 
effect of sulindac on PRA was always less than that of indomethacin. 
By contrast no differences were found in effect on renal function, ex-
pressed as serum creatinine or as endogenous creatinine clearance, as 
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well as renal prostaglandin synthesis (see later). So with regard to 
these parameters no "kidney sparing" properties could be ascribed to 
sulindac as has been suggested in the literature. 
In summary this study indicates at several points on a discrepancy be­
tween sulindac and other NSAID in interaction with hydrochlorothiazide, 
however apparently without consequences for its blood pressure lowering 
effect. 
_ Are differences in the inhibition of renal prostaglandin synthesis 
responsible for the disparities between sulindac and indomethacin? 
CHAPTER k points on the relativity of the determination of urinary 
prostaglandins as a reflection of their intrarenal synthesis. Particu­
larly contamination with seminal fluid disturbs the measurement heavi­
ly. However we found the РСЕг/РСГгц ratio to be an useful index to 
detect wheter the urine is contaminated with seminal fluid. In addition 
this chapter reports on the results of the measurements of four differ­
ent prostaglandins i.e. PGE2, PGF"2a» 6 keto PGFi
a
 and thromboxane 
B2 (TXB2) in normal volunteers and patients with essential hyper­
tension. 
Males had higher excretions of PGEj and PGF2a» than females. 
But no significant differences were found between healthy volunteers 
and patients with essential hypertension, except higher TXB2 excretions 
in hypertensive females. These data do not support any hypothesis of 
altered basal intrarenal synthesis of prostaglandins in patients with 
essential hypertension. Using the РСЕг/РСГга ratio, the urinary 
excretion of the same four prostaglandins, was measured in 11 patients 
with essential hypertension after 4 weeks of treatment with either 
placebo, hydrochlorothiazide alone or in combination with sulindac or 
indomethacin (CHAPTER 5). Both NSAID appeared to reduce the urinary 
excretion of prostaglandins to a similar degree. 
So, these results do not support the hypothesis, that sulindac differs 
from other NSAID, particularly indomethacin, in effect on renal prosta­
glandin synthesis. 
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Do incbmethaain and sul-indac influence hydrochlorothiazide 
farmacokinetics? 
To resolve this question, firstly, we developed a new HPLC method for 
the determination of hydrochlorothiazide in plasma and urine, since 
previous methods had all their disadvantages for instance different 
assay for plasma and urine, or an insufficient limit of detection. 
CHAPTER 6 describes our method, using chlorothiazide as an internal 
standard. 
CHAPTER 7 and θ give the results of two studies on a possible pharmaco­
kinetic interaction between hydrochlorothiazide on one hand and sulin-
dac and indomethacin on the other hand. These studies were performed in 
В healthy volunteers, and in 8 patients with essential hypertension 
respectively. Particularly, sulindac was observed to diminish the renal 
clearance of hydrochlorothiazide, when added for one week to the diure­
tic, although in hypertensive patients the effect did not reach the 
level of statistical significance. However, from indomethacin no effect 
on renal hydrochlorothiazide clearance could be demonstrated neither in 
healthy volunteers, nor in hypertensive patients. 
Ultimately these results indicate that the presence of distinct effects 
on renal prostaglandins as suggested by several authors probably is 
anyhow a too simple explanation for the differences between sulindac 
and other N5AID i.e. in this case indomethacin, and that a pharmaco­
kinetic interaction should be considered as well.This opinion is sup­
ported by our data from the pharmacodynamic effects of sulindac e.g. 
the tendency not to attenuate the diuretic induced decrease of potas-
sium, and the lesser effects on body weight and PRA as compared to 
indomethacin. 
In sunmary the main conclusion of this study is that the NSAID despite 
attenuation of several effects induced by the action of hydrochloro­
thiazide do not affect the blood pressure lowering effect of this thia­
zide diuretic in a clinically relevant way. This conclusion holds also 
for sulindac, although this NSAID behaves quite differently in inter­
action with some effects of hydrochlorothiazide. 
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CHAPTER 11 
NEDERLAMISE SAMENVATTING 
Dit laatste, 11e hoofdstuk, geeft een hoofdstuksgewijze uitgebreide 
Nederlandstalige samenvatting, in eenvoudige termen, van dit proef-
schrift. 
Hoofdstuk 1 
In dit hoofdstuk wordt het doel van het onderzoek uiteengezet. 
Diuretica, anders gezegd "piastabletten" worden al jaren gebruikt bij 
de behandeling van hoge bloeddruk (hypertensie), een ziekte, die indien 
onbehandeld, op de lange duur leidt tot vroegtijdige verkalking van 
bloedvaten, zogenaamde athérosclérose. Deze verkalking van bloedvaten 
kan op zijn beurt weer andere ziekten veroorzaken, zoals een vroegtij-
dig hartinfarct of een beroerte. 
Diuretica verlagen de bloeddruk waarschijnlijk op 2 manieren, in eerste 
instantie door de uitschelding van water en zout door de nier te bevor-
deren, en bij chronische behandeling waarschijnlijk ook door een direc-
te invloed op bloedvaten. 
Niet steroidale antunflammatoire analgetica (NSAID) zijn pijnstillende 
medicamenten, die voornamelijk bij rheumatische ziekten, maar ook bij 
zogenaamde "slijtage van de gewrichten" (arthrose), worden gebruikt ter 
bestrijding van de pijn en de ontsteking bij deze ziekten. 
Het is reeds geruime tijd bekend dat NSAID de werkzaamheid van diureti-
ca kunnen verminderen, vooral bij ziekten, die gepaard gaan met opho-
ping van vocht in de weefsels (oedeem), en die gewoonlijk met diuretica 
worden behandeld. 
Deze bijwerking hangt samen met het werkingsmechanisme van NSAID n.l. 
hun vermogen om de aanmaak van de zogenaamde "Prostaglandines" te rem-
men. Prostaglandines zijn hormonen die o.a. een rol spelen bij een aan-
tal functies van de nier zoals de uitschelding van water en zout en 
waarschijnlijk ook bij de regulatie van de bloeddruk (zie hoofdstuk 2). 
Of NSAID ook het bloeddrukverlagende effect van diuretica tenietdoen, 
is in de literatuur een controversieel onderwerp. Sommige onderzoekers 
vonden dit wel, andere niet. De belangnjkse vraagstelling van het on-
derzoek waarvan dit proefschrift verslag doet is of NSAID het effect 
van diuretica antagoneren en met name hun effect op de bloeddruk. 
Als dit het geval zou zijn dan zou dat voor hypertensiepatienten be-
langrijke, en op den duur misschien wel schadelijke gevolgen kunnen 
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hebben, als zij met NSAID behandeld zouden moeten worden. Zowel hyper-
tensie als rheumatische ziekten komen vaak voor en de situatie dat een 
patiënt beide soorten medicijnen nodig heeft is zeker niet uitzonder-
lijk. 
Als diureticum werd hydrochlorothiazide (Dichlotride ) gebruikt, en dit 
werd in verschillende studies gecombineerd met diverse NSAID nl. indo-
methacine (Indocid ), Naproxen (Naprosyne ), Ibuprofen (Brufen ), di-
clofenac (Voltaren ) en sulindac (Clinoril ). Het laatstgenoemde ge-
neesmiddel, sulindac neemt mogelijk een aparte plaats in onder de 
NSAID. Het zou de aanmaak van Prostaglandines in de nier niet remmen, 
daardoor minder invloed hebben op de functie van dit orgaan, en dus 
theoretisch voordeel kunnen hebben boven andere NSAID. 
De tweede vraag van dit proefschrift was dan ook of sulindac een gun-
stiger invloed heeft heeft op de bloeddruk van met hydrochlorothiazide 
behandelde hypertensiepatiënten, dan andere NSAID en of dit komt door-
dat dit NSAID de aanmaak van Prostaglandines niet beïnvloedt en de an-
dere wel. 
Geneesmiddelen kunnen eikaars effecten ook beïnvloeden door onderling 
de opname via de darmwand, de verspreiding in het lichaam of de uit-
scheiding via lever of nieren te beïnvloeden. Die processen, welke de 
lotgevallen van een geneesmiddel van toediening tot en met eliminatie 
beschrijven duidt men aan met de term "farmacokinetiek". Bij sommige 
geneesmiddelen-interacties is er dus sprake van zogenaamde farmacokine-
tische mechanismen. 
We onderzochten daarom tenslotte of sulindac en indomethacine wellicht 
de opname uit de darm van hydrochlorothiazide beïnvloeden of diens 
uitscheiding door de nieren. Ook op deze (farmokinetische) manier 
zouden de NSAID het effect van hydrochlorothiazide kunnen veranderen. 
Hoofdstuk 2 
Dit hoofdstuk geeft een overzicht van wat er in de literatuur bekend is 
over de vermindering van de werking van diuretica, indien men deze com-
bineert met NSAID: de zogenaamde "interactie" tussen diuretica en 
NSAID. Ook worden enkele hypotheses besproken, die dit fenomeen zouden 
kunnen verklaren. 
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De meest gangbare theorie heeft te maken met de remmende invloed van 
NSAID op de aanmaak van Prostaglandines, en met de consequenties dat 
dit kan hebben voor de functie van de nier. De nierfunctie is voor het 
organisme dermate belangrijk, dat in bijzondere omstandigheden door 
middel van speciale regelmechanismen het handhaven daarvan hoge prio-
riteit krijgt; met name bij ernstig vochtverlies bijvoorbeeld bij bra-
ken, bloedingen, maar ook bij gebruik van diuretica, wordt de functie 
van de nier in stand gehouden met behulp van een verhoogde productie 
van o.a. Prostaglandines. Remt men echter hun aanmaak, dan gaat de 
nierfunctie achteruit en daalt het vermogen van de nier om water en 
zout uit te scheiden. Omdat diuretica normaliter de uitscheiding van 
water en zout stimuleren kunnen NSAID op deze manier dus het effect van 
diuretica verminderen. Dit fenomeen namelijk de achteruitgang van nier-
functie en de vermindering van de werkzaamheid van diuretica door NSAID 
is goed gedocumenteerd aangaande de combinatie van NSAID met krachtig 
werkende diuretica (bijvoorbeeld met het bekende Lasi>P ) zoals die in 
de regel gebruikt worden bij hartfalen, of nier- en leverziekten die 
gepaard gaan met vochtophoping in de weefsels. Bij hypertensie is dit 
aanmerkelijk minder vaak beschreven, omdat deze ziekte vaak behandeld 
wordt met niet zo'n krachtige diuretica, waardoor de nier zoals dit 
wordt geformuleerd minder "Prostaglandine afhankelijk" is. Een andere 
verklaring zou echter kunnen zijn, dat Prostaglandines rechtstreeks be-
trokken zijn bij de werking van krachtige diuretica, en niet bij die 
van de andere. Tenslotte zou er ook een interactie kunnen optreden tus-
sen NSAID en diuretica, als NSAID de opname van diuretica uit de darm 
en de uitscheiding hiervan door de nier beïnvloeden (een zogenaamde 
pharmacokinetische interactie). 
Hoofdstuk 3 
Dit hoofdstuk is een eerste, waarin eigen onderzoeksresultaten worden 
besproken. Dit betrof 10 patiënten met essentiële hypertensie (= hoge 
bloeddruk zonder bekende oorzaak) die gedurende 28 weken behandeld wer-
den met hydrochlorothiazide alleen, of in combinatie met 3 verschillen-
de NSAID namelijk óf indomethacine, óf naproxen, óf sulindac, allemaal 
gedurende 4 weken en onderbroken door periodes van 4 weken waarin de 
patiënten hydrochlorothiazide alléén kregen. 
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Met hydrochlorothiazide alléén daalde de bloeddruk gemiddeld 75o (auto-
matisch én met de hand gemeten); toevoeging van de NSAID had slechts 
een lichte stijging van de bloeddruk tot gevolg na 2 weken behandeling 
met indomethacine. Echter na 4 weken was de bloeddruk met alle 3 de 
NSAID hetzelfde als met hydrochlorothiazide alléén. 
Wel antagoneerde indomethacine een paar andere effecten van hydrochlo-
rothiazide namelijk de daling van het lichaamsgewicht en van het ka-
liumgehalte van het bloed, beide directe gevolgen van de diuretische 
werking van hydrochlorothiazide. 
De belangnjkse bevinding was echter dat de NSAID de bloeddruk verla-
gende werking van hydrochlorothiazide met beïnvloedden. 
Hoofdstuk 4 
In dit hoofdstuk worden de resultaten besproken van de gedane metingen 
van 4 verschillende Prostaglandines (PGE¿, PGF2a» 6 keto PGFia en 
TXBj) m de 24 uurs urine van 26 gezonde vrijwilligers en 41 patiënten 
met essentiële hypertensie. De uitscheiding van Prostaglandines in de 
24 uurs urine wordt over het algemeen beschouwd als een maat voor de 
aanmaak van Prostaglandines in de nier. 
Voorafgaande aan dit onderzoek maten we bij een mannelijke en een vrou-
welijke gezonde vrijwilliger gedurende respectievelijk 16 en 11 opeen-
volgende dagen, de uitschelding van Prostaglandines in de 24 uurs 
urine. 
De meting van Prostaglandines gebeurde met de techniek van radioimmuno-
assay (RIA), die op het gynaecologische laboratorium te Nijmegen in de 
jaren 1977-1978 was ontwikkeld. Het bleek dat op dagen dat de 2 vrij-
willigers cohabitatie hadden gehad, de prostaglandine-uitscheiding zeer 
hoog was waarschijnlijk door de aanwezigheid van semen in de urine, 
dat, zoals bekend is, grote hoeveelheden Prostaglandines bevat. Uit de 
gegevens konden we afleiden dat de verhouding PGE2/PGF2a een goede 
maat 13 voor de aanwezigheid van semen. Als deze breuk > 0.5 is, dan is 
de urine waarschijnlijk vermengd met semen. 
De resultaten van de meting van Prostaglandines bij de 26 gezonde vrij-
willigers en 41 patiënten met hypertensie lieten geen zeer overtuigende 
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verschillen zien tussen beide groepen, behalve een hogere TXB2 uit-
scheiding bij vrouwen net hypertensie. Wel hadden mannen een hogere 
uitscheiding van PGE2 en PGF2t dan vrouwen. Het onderzoek toont aan, 
dat men niet zonder meer kan zeggen dat Prostaglandines in de urine een 
afspiegeling zijn van de aanmaak van Prostaglandines in de nier en dat 
patiënten met essentiële hypertensie waarschijnlijk geen andere basale 
uitscheiding van Prostaglandines hebben, dan gezonde vrijwilligers. 
Hoofdstuk 5 
De hier besproken studie, de meest omvangrijke in dit proefschrift 
hield zich vooral bezig met de mogelijke verschillen tussen sulindac en 
indomethacine in interactie met hydrochlorothiazide. Vijfentwintig pa-
tiënten met essentiële hypertensie werkten mee aan dit onderzoek. Zij 
werden gedurende 28 weken behandeld met óf placebo, óf met hydrochloro-
thiazide alléén, óf met hydrochlorothiazide in combinatie met indo-
methacine of sulindac. Elke behandelingsperiode duurde 4 weken. De bei-
de NSAID werden toegediend volgens een zogenaamd dubbel blind, gerando-
miseerd cross over schema. 
Om de 2 weken werd de bloeddruk (automatisch en met de hand) gemeten, 
en om de 4 weken deden we laboratoriumonderzoek. De Prostaglandines 
werden bij 11 patiënten gemeten in de 24 uurs urine aan het einde van 
elke 4 wekelijkse periode. 
Hydrochlorothiazide alléén deed de bloeddruk, ten opzichte van placebo, 
dalen met 8%. Beide NSAID veroorzaakten slechts een geringe stijging 
van de bloeddruk, wanneer ze toegevoegd werden aan hydrochlorothia-
zide. Wat dit betreft was er geen verschil tussen sulindac en indo-
methacine. 
Wel antagoneerde indomethacine een aantal andere effecten van het diu-
reticum, en sulindac niet, namelijk de daling van het lichaamsgewicht 
en van het kaliumgehalte van het bloed. Ook daalde het renine in het 
bloed tijdens indomethacine en niet tijdens sulindac (renine is een 
hormoon, dat een rol speelt bij de regulatie van het natrium- en ka-
liumgehalte van het bloed). 
Daarentegen veroorzaakten beide NSAID een daling in gelijke orde van 
grootte van de 24 uurs uitscheiding van Prostaglandines in de urine. 
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Geen van beide NSAID had in deze proefopzet schadelijke effecten op de 
nierfunctie. 
Deze studie toonde opnieuw aan, dat NSAID de bloeddrukverlagende wer-
king van hydrochlorothiazide, althans bij het onderzochte type patiën-
ten, met verminderen. Dit geldt zowel voor indomethacine als voor su-
lindac. Wij konden niet bevestigen, dat het verschil tussen beide NSAID 
en interactie met een aantal andere effecten van hydrochlorothiazide, 
berust op het feit, dat sulindac de synthese van Prostaglandines in de 
nier minder remt dan indomethacine. 
Hoofdstuk 6 
Hierin wordt een nieuwe methode, door ons ontwikkeld voor de meting van 
hydrochlorothiazide in plasma en urine, beschreven. Dit wordt gedaan 
met de methode van de "hoge druk vloeistof chromatografie" (HPLC). Hoe-
wel er al een groot aantal HPLC-methoden zijn, hebben alle toch hun na-
delen. De detectiegrens van onze methode bedraagt 0.Q25 μg/ml voor 
bloed en 0.5 μg/ml voor urine. 
Hoofdstuk 7 
Dit hoofdstuk beschrijft de resultaten van een studie naar de interac­
tie van sulindac en indomethacine met hydrochlorothiazide bij θ gezonde 
vrijwilligers. 
Deze vrijwilligers werden gedurende 4 weken behandeld met hydrochloro­
thiazide, in de 1e en 3e week alleen, en in de 2e en 4e week gecombi­
neerd met óf sulindac óf indomethacine. Bloeddrukveranderingen werden 
niet gevonden. Wel steeg tijdens indomethacine het lichaamsgewicht, het 
kaliumgehalte van het bloed en daalde het renine. Tijdens sulindac wa-
ren er geen gewichtsveranderingen, wel daalde het renine, maar minder 
dan met indomethacine, terwijl het kaliumgehalte juist leek te dalen 
tijdens gecombineerde behandeling met dit NSAID. 
Üp het einde van elke week werd op θ tijdstippen (van 1 uur tot 24 uur 
na inname van de tablet) de concentratie van hydrochlorothiazide in het 
bloed en de urine bepaald. Indomethacine veroorzaakte geen verandenn-
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gen in deze concentratie. Sulindac daarentegen veranderde de verhouding 
tussen de concentratie van hydrochlorothiazide in het bloed en de uit-
scheidingssnelheid van het diureticum in de urine (=renale klaring). 
Bovendien werd bij 2 personen met de relatief kleinste nierfunctie van 
de groep een opvallend hoge concentratie van hydrochlorothiazide gevon-
den. De belangrijkste conclusie die uit onze studie getrokken kan wor-
den is dat sulindac mogelijk de renale klaring beïnvloedt, dat wil zeg-
gen verminderd en indomethacine niet. Daarentegen verandert indometha-
cine de werking van hydrochlorothiazide het sterkste. 
Hoofdstuk θ 
Dit beschrijft een studie met in principe dezelfde opzet als die in 
hoofdstuk 7, maar nu bij patiënten met essentiële hypertensie. Oor-
spronkelijk waren В patiënten gevraagd om mee te doen; uiteindelijk 
voltooiden slechts 6 patiënten het gehele onderzoeksprotocol. 
De patiënten werden gedurende 4 weken behandeld met hydrochlorothia-
zide, in de 2e en 4 week werden hieraan öf indomethacine óf sulindac 
toegevoegd. Het bleek, dat bloeddruk en kaliungehalte tijdens indome-
thacinegebruik hoger waren dan met sulindac. Beide NSAID veroorzaakten 
een stijging van het lichaamsgewicht, 
Aan het einde van elke week werd weer de concentratie van hydrochloro-
thiazide bepaald in bloed en urine op θ tijdstippen na inname van het 
diureticum. Hierbij leek sulindac de renale klaring van hydrochloro­
thiazide sterker te beïnvloeden d.w.z. te verminderen, dan indometha-
cine. Echter de verschillen waren niet statistisch significant. 
Desondanks toont de studie aan, dat men rekening dient te houden met de 
invloed van NSAID op opname en uitscheiding van diuretica en dat men 
niet alleen moet kijken naar effecten op Prostaglandines, om een inter-
actie tussen NSAID en diuretica te verklaren. Verder toont de studie 
wel degelijk verschillen in invloed van indomethacine en sulindac op de 
bloeddruk aan, als men deze NSAID kortdurend combineert met hydrochlo-
rothiazide. 
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Hoofdstuk 9 
De studie, die in dit hoofdstuk wordt beschreven, had in feite dezelf-
de opzet als die in hoofdstuk 3, maar er werden andere NSAID gebruikt. 
Acht patiënten werden gedurende 28 weken behandeld met hydrochlorothia-
zide alleen of in combinatie met hetzij sulindac, Ibuprofen, of diclo-
fenac, allemaal gedurende 4 weken, en steeds onderbroken door periodes 
van 4 weken, waarin hydrochlorothiazide alléén wordt gegeven. Elke 2 
weken werden bloeddruk en gewicht gemeten en om de 4 weken deden we 
laboratoriumonderzoek. 
Behalve een stijging van de systolische bloeddruk tijdens Ibuprofen 
bracht de toevoeging van de NSAID en hydrochlorothiazide, geen verande-
ring teweeg in de bloeddruk. Bovendien kon de bloeddrukstijging tijdens 
Ibuprofen alleen aangetoond worden met de "handmeting" en niet met au-
tomatische bloeddrukmeting. Andermaal toont deze studie dus aan dat 
NSAID het bloeddrukverlagend effect van hydrochlorothiazide niet of 
slechts kortdurend beïnvloeden. 
Wel kon een duidelijke stijging van het lichaamsgewicht aangetoond wor-
den, tijdens Ibuprofen en diclofenac en dit keer ook tijdens sulindac, 
maar dit laatste slechts na 2 weken en niet meer na 4 weken behande-
ling. Belangrijke veranderingen van nierfunctie of het kallumgehalte 
werden niet gevonden. 
Hoofdstuk 10 
Dit hoofdstuk betreft de conclusies en een Engelstalige samenvatting. 
1. NSAID zwakken de bloeddrukverlagende werking van hydrochlorothiazide 
niet af bij patiënten met lichte tot matige essentiële hypertensie. 
Er treedt hooguit een geringe en voorbijgaande stijging van de 
bloeddruk op, als men NSAID combineert met hydrochlorothiazide. 
2. Sulindac heeft eveneens geen klinisch relevante invloed op het 
bloeddrukverlagend effect van hydrochlorothiazide bij chronische 
toediening aan patiënten met lichte en matige essentiële hyperten-
sie. Daarentegen zwakt sulindac de verlaging van het lichaamsgewicht 
en het kallumgehalte en de stijging van het renine onder invloed van 
hydrochlorothiazide, minder sterk af dan indomethacine of andere 
NSAID. 
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3. Het verschil in interactie met bepaalde effecten van hydrochloro-
thiazide tussen sulindac en andere NSAID (zoals indomethacine) kan 
niet verklaard worden door een simpel onderscheid, als zou sulindac 
niét en de andere NSAID wél de synthese van Prostaglandines in de 
nier remmen. 
4. Het verschil in interactie met hydrochlorothiazide tussen sulindac 
en de andere NSAID kan misschien worden verklaard doordat sulindac 
de renale klaring van hydrochlorothiazide beïnvloedt en de andere 
NSAID zoals indomethacine, niet. 
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MOORDEN VAN DANK 
Velen hebben bijgedragen aan het tot stand komen van dit proefschrift 
en hen allen ben ik veel dank verschuldigd. In de eerste plaats geldt 
dit voor de patiënten en de gezonde vrijwilligers, die zo bereidwillig 
waren om mee te werken aan de vaak langdurige en tijdrovende onderzoe-
ken. 
Vervolgens de verpleegkundigen en doktersassistenten van de polikliniek 
Inwendige Ziekten (verpleegkundig hoofd: M. Cousijn). Zij voerden met 
grote nauwgezetheid de vele prikprogramma's uit. 
De vele laboratoriumbepalingen werden gedaan op het Klinisch Chemisch 
Laboratoriun van de afdeling Interne Geneeskunde (hoofd: prof. Dr. 
A.P. Janssen) en de radioimmunoassays van aldosteron en plasma renine 
activiteit op het laboratorium voor Chemische en Experimentele Endocri-
nologie (hoofd: Prof. Dr. Th. Benraad). 
De Prostaglandines werden, eveneens met radioimmunoassay, onder leiding 
van Dr. C.M.G. Thomas, bepaald door Rob van de Berg op het laboratorium 
voor Obstetrie en Gynaecologie (hoofd: Drs. P. Houx). 
Yuen Tan van de afdeling Farmacologie, werkgroep Klinische Farmacologie 
en Farmacokinetiek, deed de hydrochlorothiazide bepalingen. 
De heer J. Berris van de Medische Tekenkamer tekende de figuren voor 
dit proefschrift en deze werden gefotografeerd door de medewerkers van 
de afdeling Medische Fotografie (hoofd: de heer A. Reijnen). 
De medewerkers van de Medische Bibliotheek (hoofd destijds de heer E. 
de Graaff, momenteel mevrouw S. Bakker) waren steeds behulpzaam bij het 
verzamelen van de literatuur. 
Gemma Wessel - Hoogstraten, Ineke ten Have en Dinie Graven hebben alle-
maal een bijdrage geleverd aan het typewerk en aan het drukklaar maken 
van het manuscript. Het overgrote deel van dit werk werd echter gedaan 
door Anky Verweijen. 
Tenslotte dank ik de collegae van de afdeling Algemene Interne Genees-
kunde voor de prettige en stimulerende samenwerking gedurende de afge-
lopen jaren en Dr. L. Offerhaus en Dr. С Teygeler voor hun begrip, als 
de rapporten over de geneesmiddelen wat langer op zich lieten wachten. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 1 november 1951 te 
Tegelen (L). In 1970 behaalde hij het diploma gymnasium ρ aan het St. 
Thomascollege te Venlo. Aansluitend studeerde hij Geneeskunde aan de 
Katholieke Universiteit te Nijmegen. In 1975 werd het doktoraalexamen 
behaald en in 1978 het artsexamen. In juni 1978 begon hij met de oplei­
ding tot internist in de Kliniek voor Inwendige Ziekten van het St. 
Radboudziekenhuis (hoofd destijds Prof. Dr. С Majoor, momenteel Prof. 
Dr. A. van 't Laar). In juni 1983 werd hij als specialist ingeschre­
ven. Sedert maart 1984 is hij in dienst van het ministerie van WVC bij 
het college ter beoordeling van geneesmiddelen, als lid van de kli­
nische werkgroep (hoofd Dr. L. Offerhaus). Hij is gestationeerd in de 
kliniek voor Inwendige Ziekten verbonden aan de afdeling Algemene 
Interne Geneeskunde (Hoofd Prof. Dr. A. van 't Laar), en aan de werk­
groep Klinische Farmacologie en Farmacokinetiek (hoofd Prof. Dr. 
C.A.M, van Ginneken). 
Hij is getrouwd met Ria Oomen. 
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STELLINGEN 
I 
De vermindering van de bloeddrukverlagende werking van hydrochlorothia-
zide door met steroidale antiinflammatoire analgetica is bij patiënten 
met lichte tot matige essentiële hypertensie hooguit een tijdelijk en 
een klinisch weinig relevant fenomeen. 
(dit woef schrift) 
II 
Sulindac verschilt van indomethacine in interactie met de effecten van 
hydrochlorothiazide op lichaamsgewicht, plasma kalium en de plasma re-
nine activiteit; echter dit heeft geen consequenties voor het bloed-
drukverlagend effect van hydrochlorothiazide bij de in de eerste stel-
ling genoemde categorie patiënten. 
(dit proefschrift) 
III 
Zowel sulindac als indomethacine remmen de synthese van Prostaglandines 
in de nier. 
(dit proefschrift) 
IV 
Farmacokinetische factoren kunnen een rol spelen bij het verschil tus-
sen sulindac en indomethacine in interactie met hydrochlorothiazide. 
(dit proefschrift) 
V 
Patienten met essentiële hypertensie hebben geen andere basale Prosta-
glandine excretie in de urine dan gezonde vrijwilligers. 
(dit proefschrift) 
VI 
Als de verhouding van de concentraties PGE2 en PGF2a in urine groter 
is dan 0,5, is deze urine gecontamineerd met semen. 
(dit proefschrift) 
VII 
Niet steroidale antiinflammatoire analgetica verminderen de werkzaam-
heid van diuretica vooral als de nier functie "Prostaglandine afhanke-
lijk" is, zoals bijvoorbeeld bij sterk verminderd circulerend volume. 

Vili 
Het antihypertensieve effect van hydralazine is bij "slow-acetylators" 
sterker dan bij "fast-acetylators", althans bij patiënten met normale 
nierfunctie. 
(P.P. Koopmans e.a. Neth J Med 1984; 27: 69-73) 
IX 
Diuretica hebben voor zover thans vaststaat geen consistente invloeden 
op cholesterol, triglyceride of HDL. 
(o.a. met niet gepubliceerde waarneming) 
X 
Sommige patiënten met hypertensie, die met de "step-up" methode zijn 
behandeld kunnen na verloop van tijd ook op de "step-down" manier be-
handeld worden. 
(Finnerty: Am J Med 1984; 52: 1304-1307) 
XI 
Vanuit het oogpunt van kwaliteit van patiëntenzorg zou men in de beoor-
deling van ter registratie aangeboden geneesmiddelen niet alleen de 
balans werkzaamheid-schadelijkheid moeten betrekken, maar ook of het 
geneesmiddel een innoverende aanwinst voor de therapie betekent. 
XII 
Het basisonderwijs interne geneeskunde (BOIG) zal alleen dán de oplei-
ding tot internist verbeteren als het een basis vormt voor het dage-
lijks praktisch, internistisch, handelen. 
XIII 
Het nut van allerlei zalven, balsems, schudsels of vochtabsorberende 
korrels bij de behandeling van decubitus is niet bewezen en het gebruik 
van deze medicamenten dient hierbij dan ook, op zijn minst, sterk be-
perkt te worden. 
XIV 
De werknemers van de Nijmeegse faculteit der geneeskunde en van het 
St. Radboudziekenhuis doen in het personeelsrestaurant meer informatie 
op dan in welke andere ruimte ook. 
P.P. Koopmans, 9 mei 1985 



